



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number : **0 675 110 A1**

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number : **95302166.4**

(51) Int. Cl.<sup>8</sup> : **C07D 209/22, A61K 31/40**

(22) Date of filing : **31.03.95**

(30) Priority : **01.04.94 US 221916**

(43) Date of publication of application :  
**04.10.95 Bulletin 95/40**

(84) Designated Contracting States :  
**AT BE CH DE DK ES FR GB GR IE IT LI LU NL  
PT SE**

(71) Applicant : **ELI LILLY AND COMPANY**  
**Lilly Corporate Center**  
**Indianapolis Indiana 46285 (US)**

(72) Inventor : **Bach, Nicholas James**  
**7215 South Meridian Street**  
**Indianapolis, Indiana 46217 (US)**  
Inventor : **Dillard, Robert Delane**  
**7243 West 92nd Street**  
**Zionsville, Indiana 46077 (US)**  
Inventor : **Draheim, Susan Elizabeth**  
**6125 Burlington Avenue**  
**Indianapolis, Indiana 46220 (US)**

(74) Representative : **Hudson, Christopher Mark et al**  
**Lilly Industries Limited**  
**European Patent Operations**  
**Erl Wood Manor**  
**Windlesham Surrey GU20 6PH (GB)**

(54) **1H-Indole-3-glyoxylamide sPLA2 inhibitors.**

(57) A class of novel 1H-indole-3-glyoxylamides is disclosed together with the use of such indole compounds for inhibiting sPLA<sub>2</sub> mediated release of fatty acids for treatment of conditions such as septic shock.

*shows 2-NH<sub>2</sub>  
not further substituted  
which = site of  
substitution in L.A.*

EP 0 675 110 A1

This invention relates to novel 1H-indole-3-glyoxylamides useful for inhibiting sPLA<sub>2</sub> mediated release of fatty acids for conditions such as septic shock.

The structure and physical properties of human non-pancreatic secretory phospholipase A<sub>2</sub> (hereinafter called, "sPLA<sub>2</sub>") has been thoroughly described in two articles, namely, "Cloning and Recombinant Expression of Phospholipase A<sub>2</sub> Present in Rheumatoid Arthritic Synovial Fluid" by Seilhamer, Jeffrey J.; Pruzanski, Waldemar; Vadas Peter; Plant, Shelley; Miller, Judy A.; Kloss, Jean; and Johnson, Lorin K.; The Journal of Biological Chemistry, Vol. 264, No. 10, Issue of April 5, pp. 5335-5338, 1989; and "Structure and Properties of a Human Non-pancreatic Phospholipase A<sub>2</sub>" by Kramer, Ruth M.; Hession, Catherine; Johansen, Berit; Hayes, Gretchen; McGray, Paula; Chow, E. Pingchang; Tizard, Richard; and Pepinsky, R. Blake; The Journal of Biological Chemistry, Vol. 264, No. 10, Issue of April 5, pp. 5768-5775, 1989; the disclosures of which are incorporated herein by reference.

It is believed that sPLA<sub>2</sub> is a rate limiting enzyme in the arachidonic acid cascade which hydrolyzes membrane phospholipids. Thus, it is important to develop compounds which inhibit sPLA<sub>2</sub> mediated release of fatty acids (e.g., arachidonic acid). Such compounds would be of value in general treatment of conditions induced and/or maintained by overproduction of sPLA<sub>2</sub>; such as septic shock, adult respiratory distress syndrome, pancreatitis, trauma, bronchial asthma, allergic rhinitis, rheumatoid arthritis, and etc.

The article, "Recherches en serie indolique. VI sur tryptamines substituees", by Marc Julia, Jean Igolen and Hanne Igolen, Bull. Soc. Chim. France, 1962, pp. 1060-1068, describes certain indole-3-glyoxylamides and their conversion to tryptamine derivatives.

The article, "2-Aryl-3-Indoleglyoxylamides (FGIN-1): A New Class of Potent and Specific Ligands for the Mitochondrial DBI Receptor (MDR)" by E. Romeo, *et al.*, The Journal of Pharmacology and Experimental Therapeutics, Vol. 262, No. 3, (pp. 971-978) describes certain 2-aryl-3-indoleglyoxylamides having research applications in mammalian central nervous systems.

The abstract, "Fragmentation of N-benzylindoles in Mass Spectrometry"; Chemical Abstracts, Vol. 67, 1967, 73028h, reports various benzyl substituted phenols including those having glyoxylamide groups at the 3 position of the indole nucleus.

European Patent 490263 discloses oxoacetamide derivatives of indoles having serotonin receptor activity.

U.S. Patent No. 3,449,363 describes trifluoromethylindoles having glyoxylamide groups at the 3 position of the indole nucleus. These compounds are stated to be analgesics in antagonizing phenyl-p-quinone "writhing syndrome."

U.S. Patent No. 3,351,630 describes alpha-substituted 3-indolyl acetic acid compounds and their preparation inclusive of glyoxylamide intermediates.

U.S. Patent No. 2,825,734 describes the preparation of 3-(2-amino-1-hydroxyethyl) indoles using 3-indole glyoxylamide intermediates such as 1-phenethyl-2-ethyl-6-carboxy-N-propyl-3-indoleglyoxylamide (see, Example 30).

U.S. Patent No. 4,397,850 prepares isoxazolyl indolamines using glyoxylamide indoles as intermediates.

U.S. Patent No. 3,801,594 describes analgesics prepared using 3-indole glyoxylamide intermediates.

The article, "No. 565. - Inhibiteurs d'enzymes. XII. - Preparation de (propargyramino-2 ethyl)-3 indoles" by A. Alemanhy, E. Fernandez Alvarez, O. Nieto Lopey and M. E. Rubio Herraes; Bulletin Do La Societe Chimique De France, 1974, No. 12, pgs. 2883-2888 describes various indolyl-3 glyoxamides which are hydrogen substituted on the 6 membered ring of the indole nucleus.

The article "Indol-Umlagerung von 1-Diphenylamino-2,3-dihydro-2,3-pyrroldionen" by Gert Kollenz and Christa Labes; Liebigs Ann. Chem., 1975, pgs. 1979-1983 describes phenyl substituted 3-glyoxylamides.

It is desirable to develop new compounds and treatments for sPLA<sub>2</sub> induced diseases.

This invention is a novel use of the class of compounds known as 1H-indole-3-glyoxylamides to inhibit mammalian sPLA<sub>2</sub> mediated release of fatty acids.

This invention is also novel classes of 1H-indole-3-glyoxylamides having potent and selective effectiveness as inhibitors of mammalian sPLA<sub>2</sub>.

This invention is also pharmaceutical compositions containing the 1H-indole-3-glyoxylamides of the invention.

This invention is also a method of preventing and treating septic shock, adult respiratory distress syndrome, pancreatitis, trauma, bronchial asthma, allergic rhinitis, rheumatoid arthritis, and related diseases in mammals by contact with a therapeutically effective amount of the 1H-indole-3-glyoxylamides of the invention.

#### Definitions:

The 1H-indole-3-glyoxylamides of the invention employ certain defining terms as follows:

The term, "alkyl" by itself or as part of another substituent means, unless otherwise defined, a straight or

branched chain monovalent hydrocarbon radical such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tertiary butyl, isobutyl, sec-butyl, n-pentyl, and n-hexyl.


The term, "alkenyl" employed alone or in combination with other terms means a straight chain or branched monovalent hydrocarbon group having the stated number range of carbon atoms, and typified by groups such as vinyl, propenyl, crotonyl, isopentenyl, and various butenyl isomers.

The term, "hydrocarbyl" means an organic group containing only carbon and hydrogen.

The term, "halo" means fluoro, chloro, bromo, or iodo.

The term, "heterocyclic radical", refers to radicals derived from monocyclic or polycyclic, saturated or unsaturated, substituted or unsubstituted heterocyclic nuclei having 5 to 14 ring atoms and containing from 1 to 3 hetero atoms selected from the group consisting of nitrogen, oxygen or sulfur. Typical heterocyclic radicals are pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, phenylimidazolyl, triazolyl, isoxazolyl, oxazolyl, thiazolyl, thiadiazolyl, indolyl, carbazolyl, norharmanyl, azaindolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, indazolyl, imidazo(1,2-A)pyridinyl, benzotriazolyl, anthranilyl, 1,2-benzisoxazolyl, benzothiazolyl, purinyl, pyridinyl, dipyridyl, phenylpyridinyl, benzylpyridinyl, pyrimidinyl, phenylpyrimidinyl, pyrazinyl, 1,3,5-triazinyl, quinoliny, phthalazinyl, quinazolinyl, and quinoxaliny.


The term, "carbocyclic radical" refers to radicals derived from a saturated or unsaturated, substituted or unsubstituted 5 to 14 membered organic nucleus whose ring forming atoms (other than hydrogen) are solely carbon atoms. Typical carbocyclic radicals are cycloalkyl, cycloalkenyl, phenyl, naphthyl, norbornanyl, bicycloheptadienyl, tolulyl, xylenyl, indenyl, stilbenyl, terphenyl, diphenylethylenyl, phenyl-cyclohexenyl, acenaphthylenyl, and anthracenyl, biphenyl, bibenzyl and related bibenzyl homologues represented by the formula (bb),




where n is a number from 1 to 8.

The term, "non-interfering substituent", refers to radicals suitable for substitution at positions 4, 5, 6, and/or 7 on the indole nucleus (as hereinafter depicted in Formula I) and radical(s) suitable for substitution on the heterocyclic radical and carbocyclic radical as defined above. Illustrative non-interfering radicals are C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> alkenyl, C<sub>1</sub>-C<sub>8</sub> alkynyl, C<sub>7</sub>-C<sub>12</sub> aralkyl, C<sub>7</sub>-C<sub>12</sub> alkaryl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkenyl, phenyl, tolulyl, xylenyl, biphenyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, C<sub>1</sub>-C<sub>8</sub> alkenyloxy, C<sub>1</sub>-C<sub>8</sub> alkynyloxy, C<sub>2</sub>-C<sub>12</sub> alkoxyalkyl, C<sub>2</sub>-C<sub>12</sub> alkoxyalkyloxy, C<sub>2</sub>-C<sub>12</sub> alkylcarbonyl, C<sub>2</sub>-C<sub>12</sub> alkylcarbonylamino, C<sub>2</sub>-C<sub>12</sub> alkoxyamino, C<sub>2</sub>-C<sub>12</sub> alkoxyaminocarbonyl, C<sub>1</sub>-C<sub>12</sub> alkylamino, C<sub>1</sub>-C<sub>8</sub> alkylthio, C<sub>2</sub>-C<sub>12</sub> alkylthiocarbonyl, C<sub>1</sub>-C<sub>8</sub> alkylsulfinyl, C<sub>1</sub>-C<sub>8</sub> alkylsulfonyl, C<sub>2</sub>-C<sub>8</sub> haloalkoxy, C<sub>1</sub>-C<sub>8</sub> haloalkylsulfonyl, C<sub>2</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> hydroxyalkyl, -C(O)O(C<sub>1</sub>-C<sub>8</sub> alkyl), -(CH<sub>2</sub>)<sub>n</sub>-O-(C<sub>1</sub>-C<sub>8</sub> alkyl), benzyloxy, phenoxy, phenylthio, -(CONHSO<sub>2</sub>R), -CHO, amino, amidino, bromo, carbamyl, carboxyl, carbalkoxy, (CH<sub>2</sub>)<sub>n</sub>-CO<sub>2</sub>H, chloro, cyano, cyanoguanidinyl, fluoro, guanidino, hydrazide, hydrazino, hydrazido, hydroxy, hydroxyamino, iodo, nitro, phosphono, -SO<sub>3</sub>H, thioacetal, thiocarbonyl, and C<sub>1</sub>-C<sub>8</sub> carbonyl; where n is from 1 to 8. The term, "acidic group" means an organic group which when attached to an indole nucleus, through suitable linking atoms (hereinafter defined as the "acid linker"), acts as a proton donor capable of hydrogen bonding. Illustrative of an acidic group are the following:


-5-tetrazolyl,  
-SO<sub>3</sub>H,



5




10




15

20




25




30

35




40


45



50


55








where  $n$  is 1 to 8,  $R_{89}$  is a metal or  $C_1$ - $C_{10}$  alkyl, and  $R_{99}$  is hydrogen or  $C_1$ - $C_{10}$  alkyl.

10 The words, "acid linker" refer to a divalent linking group symbolized as,  $-(L_a)-$ , which has the function of joining the 4 or 5 position of the indole nucleus to an acidic group in the general relationship:



20 The words, "acid linker length", refer to the number of atoms (excluding hydrogen) in the shortest chain of the linking group  $-(L_a)-$  that connects the 4 or 5 position of the indole nucleus with the acidic group. The presence of a carbocyclic ring in  $-(L_a)-$  counts as the number of atoms approximately equivalent to the calculated diameter of the carbocyclic ring. Thus, a benzene or cyclohexane ring in the acid linker counts as 2 atoms in calculating the length of  $-(L_a)-$ . Illustrative acid linker groups are;





(c)

wherein, groups (a), (b), and (c) have acid linker lengths of 5, 7, and 2, respectively.


The term, "amine", includes primary, secondary and tertiary amines.

The terms, "mammal" and "mammalian" include human.

The term, "alkylene chain of 1 or 2 carbon atoms" refers to the divalent radicals,  $-\text{CH}_2\text{-CH}_2-$  and  $-\text{CH}_2-$ .

#### The 1H-indole-3-glyoxylamide Compounds of the Invention:

The compounds of the invention have the general formula (I);



(I)

wherein ;

each X is independently oxygen or sulfur;

R<sub>1</sub> is selected from groups (a), (b) and (c) where;

(a) is C<sub>7</sub>-C<sub>20</sub> alkyl, C<sub>7</sub>-C<sub>20</sub> alkenyl, C<sub>7</sub>-C<sub>20</sub> alkynyl, carbocyclic radical, or heterocyclic radical, or

(b) is a member of (a) substituted with one or more independently selected non-interfering substituents;

or

(c) is the group  $-(\text{L})-\text{R}_{80}$ ; where,  $-(\text{L})-$  is a divalent linking group of 1 to 12 atoms selected from carbon, hydrogen, oxygen, nitrogen, and sulfur; wherein the combination of atoms in  $-(\text{L})-$  are selected from the group consisting of (i) carbon and hydrogen only, (ii) sulfur only, (iii) oxygen only, (iv) nitrogen and hydrogen only, (v) carbon, hydrogen, and sulfur only, and (vi) and carbon, hydrogen, and oxygen only; and where R<sub>80</sub> is a group selected from (a) or (b);

R<sub>2</sub> is hydrogen, halo, C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>3</sub>-C<sub>4</sub> cycloalkyl, C<sub>3</sub>-C<sub>4</sub> cycloalkenyl,  $-\text{O}-(\text{C}_1-\text{C}_2 \text{ alkyl})$ ,  $-\text{S}-(\text{C}_1-\text{C}_2 \text{ alkyl})$ , or a non-interfering substituent having a total of 1 to 3 atoms other than hydrogen; (that is, the R<sub>2</sub> radical may contain hydrogen atoms, but the remaining atoms comprising the total of 1 to 3 are non-hydrogen);

R<sub>4</sub> and R<sub>5</sub> are independently selected from hydrogen, a non-interfering substituent, or the group,  $-(\text{L}_a)-$  (acidic group); wherein  $-(\text{L}_a)-$ , is an acid linker having an acid linker length of 1 to 4; provided, that at least one

of  $R_4$  and  $R_5$  must be the group,  $-(L_a)-$  (acidic group);

$R_6$  and  $R_7$  are each independently selected from hydrogen, non-interfering substituent, carbocyclic radicals, carbocyclic radicals substituted with non-interfering substituents, heterocyclic radicals, and heterocyclic radicals substituted with non-interfering substituents.


#### Preferred Subgroups of Compounds of Formula (I):

A preferred subclass of compounds of formula (I) are those wherein both X's are oxygen.


Another preferred subclass of compounds of formula (I) are those wherein  $R_2$  is selected from the group; halo, cyclopropyl, methyl, ethyl, propyl, -O-methyl, and -S-methyl.

Another preferred subclass of compounds of formula (I) are those wherein for  $R_1$ ,  $-(L)-$  is an alkylene chain of 1 or 2 carbon atoms.


Another preferred subclass of compounds of formula (I) are those wherein for  $R_1$ , group  $R_{80}$  is a substituted or unsubstituted group selected from the group consisting of cycloalkyl, cycloalkenyl, phenyl, naphthyl, norbornanyl, bicycloheptadienyl, tolyl, xyl, indenyl, stilbenyl, terphenyl, diphenylethylenyl, phenyl-cyclohexenyl, acenaphthylenyl, and anthracenyl, biphenyl, bibenzyl and related bibenzyl homologues represented by the formula (bb),



where  $n$  is a number from 1 to 8. Substituents for  $R_{80}$  are non-interfering radicals. Preferred substituents for group  $R_{80}$  are independently selected from halo,  $C_1$ - $C_{10}$  alkyl,  $C_1$ - $C_{10}$  alkoxy,  $-S-(C_1-C_{10} \text{ alkyl})$ , and  $C_1$ - $C_{10}$  haloalkyl radicals. Particularly preferred are compounds wherein  $R_1$  is selected from the group consisting of



and




where  $R_{10}$  is a radical independently selected from halo,  $C_1$ - $C_{10}$  alkyl,  $C_1$ - $C_{10}$  alkoxy,  $-S-(C_1-C_{10} \text{ alkyl})$ , and  $C_1$ - $C_{10}$  haloalkyl, and  $t$  is a number from 0 to 5.


Another preferred subclass of compounds of formula (I) are those wherein  $R_4$  is a substituent having an acid linker with an acid linker length of 2 or 3. Most preferred are compounds where the acidic group is selected from

-5-tetrazolyl,  
- $SO_3H$ ,

5




10




15

20




25

30




35

40






45

50




55






where n is 1 to 8,  $R_{89}$  is a metal or  $C_1$ - $C_{10}$  alkyl, and  $R_{99}$  is hydrogen or  $C_1$ - $C_{10}$  alkyl. Particularly preferred are compounds wherein the acidic group of  $R_4$  is selected from;








or salt, and prodrug (e.g., ester) derivatives thereof.

Another preferred subclass of compounds of formula (I) are those wherein  $R_4$  is a substituent having an acid linker with an acid linker length of 2 or 3 and the acid linker group,  $-(L_a)-$ , for  $R_4$  is selected from a group represented by the formula;




where Q is selected from the group  $-(\text{CH}_2)-$ ,  $-\text{O}-$ ,  $-\text{NH}-$ , and  $-\text{S}-$ , and  $R_{84}$  and  $R_{85}$  are each independently selected from hydrogen,  $C_1$ - $C_{10}$  alkyl, aryl,  $C_1$ - $C_{10}$  alkaryl,  $C_1$ - $C_{10}$  aralkyl, carboxy, carbalkoxy, and halo. Most preferred are compounds where the acid linker,  $-(L_a)-$ , for  $R_4$  is selected from the specific groups;





and




where R is alkyl.


Another preferred subclass of compounds of formula (I) are those wherein  $\text{R}_6$  is a substituent having an acid linker with an acid linker length of 3 to 8 atoms. Most preferred are compounds where the acidic group is selected from

-5-tetrazolyl,  
- $\text{SO}_3\text{H}$ ,

5




10




15

20




25

30




35






40

45



50

55




25 where  $n$  is 1 to 8,  $R_{89}$  is a metal or  $C_1$ - $C_{10}$  alkyl, and  $R_{99}$  is hydrogen or  $C_1$ - $C_{10}$  alkyl. Particularly preferred are compounds wherein the acidic group of  $R_4$  is selected from;

-CO<sub>2</sub>H  
-SO<sub>3</sub>H  
-P(O)(OH)<sub>2</sub>


or salt, and prodrug (e.g., ester) derivatives thereof.

30 Another preferred subclass of compounds of formula (I) are those wherein  $R_5$  is a substituent having an acid linker with an acid linker length of 3 to 8 atoms and the acid linker group,  $-(L_a)-$ , for  $R_5$  is selected from;




45 where  $r$  is a number from 1 to 7,  $s$  is 0 or 1, and  $Q$  is selected from the group  $-(CH_2)-$ ,  $-O-$ ,  $-NH-$ , and  $-S-$ , and  $R_{84}$  and  $R_{85}$  are each independently selected from hydrogen,  $C_1$ - $C_{10}$  alkyl, aryl,  $C_1$ - $C_{10}$  alkaryl,  $C_1$ - $C_{10}$  aralkyl, carboxy, carbalkoxy, and halo. Most preferred are compounds where the acid linker,  $-(L_a)-$ , for  $R_5$  is selected from the specific groups;

5




10

15




20

25



30


35





40

45


50



55




and



wherein  $\text{R}_{84}$  and  $\text{R}_{85}$  are each independently selected from hydrogen,  $\text{C}_1$ - $\text{C}_{10}$  alkyl, aryl,  $\text{C}_1$ - $\text{C}_{10}$  alkaryl,  $\text{C}_1$ - $\text{C}_{10}$  aralkyl, carboxy, carbalkoxy, and halo.

Another preferred subclass of compounds of formula (I) are those wherein  $\text{R}_6$  and  $\text{R}_7$  are each independently selected from hydrogen and non-interfering substituents, with the non-interfering substituents being selected from the group consisting of  $\text{C}_1$ - $\text{C}_6$  alkyl,  $\text{C}_1$ - $\text{C}_6$  alkenyl,  $\text{C}_1$ - $\text{C}_6$  alkynyl,  $\text{C}_7$ - $\text{C}_{12}$  aralkyl,  $\text{C}_7$ - $\text{C}_{12}$  alkaryl,  $\text{C}_3$ - $\text{C}_8$  cycloalkyl,  $\text{C}_3$ - $\text{C}_8$  cycloalkenyl, phenyl, tolulyl, xylenyl, biphenyl,  $\text{C}_1$ - $\text{C}_6$  alkoxy,  $\text{C}_1$ - $\text{C}_6$  alkenyloxy,  $\text{C}_1$ - $\text{C}_6$  alkynyloxy,  $\text{C}_2$ - $\text{C}_{12}$  alkoxyalkyl,  $\text{C}_2$ - $\text{C}_{12}$  alkoxyalkyloxy,  $\text{C}_2$ - $\text{C}_{12}$  alkylcarbonyl,  $\text{C}_2$ - $\text{C}_{12}$  alkylcarbonylamino,  $\text{C}_2$ - $\text{C}_{12}$  alkoxyamino,  $\text{C}_2$ - $\text{C}_{12}$  alkoxyaminocarbonyl,  $\text{C}_1$ - $\text{C}_{12}$  alkylamino,  $\text{C}_1$ - $\text{C}_6$  alkylthio,  $\text{C}_2$ - $\text{C}_{12}$  alkylthiocarbonyl,  $\text{C}_1$ - $\text{C}_6$  alkylsulfinyl,  $\text{C}_1$ - $\text{C}_6$  alkylsulfonyl,  $\text{C}_2$ - $\text{C}_6$  haloalkoxy,  $\text{C}_1$ - $\text{C}_6$  haloalkylsulfonyl,  $\text{C}_2$ - $\text{C}_6$  haloalkyl,  $\text{C}_1$ - $\text{C}_6$  hydroxyalkyl,  $-\text{C}(\text{O})\text{O}(\text{C}_1\text{-C}_6\text{ alkyl})$ ,  $-(\text{CH}_2)_n\text{-O}(\text{C}_1\text{-C}_6\text{ alkyl})$ , benzyloxy, phenoxy, phenylthio,  $-(\text{CONHSO}_2\text{R})$ ,  $-\text{CHO}$ , amino, amidino, bromo, carbamyl, carboxyl, carbalkoxy,  $-(\text{CH}_2)_n\text{-CO}_2\text{H}$ , chloro, cyano, cyanoguanidiny, fluoro, guanidino, hydrazide, hydrazino, hydrazido, hydroxy, hydroxyamino, iodo, nitro, phosphono,  $-\text{SO}_3\text{H}$ , thioacetal, thiocarbonyl, and  $\text{C}_1$ - $\text{C}_6$  carbonyl; where  $n$  is from 1 to 8.

Preferred compounds of the invention are those having the general formula (II);




wherein ;

each X is independently oxygen or sulfur;

R<sub>11</sub> is selected from groups (a), (b) and (c) where;


(a) is C<sub>7</sub>-C<sub>20</sub> alkyl, C<sub>7</sub>-C<sub>20</sub> alkenyl, C<sub>7</sub>-C<sub>20</sub> alkynyl; or a carbocyclic radical selected from the group cycloalkyl, cycloalkenyl, phenyl, naphthyl, norbornanyl, bicycloheptadienyl, tolyl, xlyenyl, indenyl, stilbenyl, terphenyl, diphenylethylenyl, phenyl-cyclohexenyl, acenaphthylenyl, and anthracenyl, biphenyl, bibenzyl and related bibenzyl homologues represented by the formula (bb),



where n is a number from 1 to 8; or

(b) is a member of (a) substituted with one or more independently selected non-interfering substituents selected from the group consisting of C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> alkenyl, C<sub>1</sub>-C<sub>8</sub> alkynyl, C<sub>7</sub>-C<sub>12</sub> aralkyl, C<sub>7</sub>-C<sub>12</sub> alkaryl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>3</sub>-C<sub>8</sub> cycloalkenyl, phenyl, tolyl, xlyenyl, biphenyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, C<sub>1</sub>-C<sub>8</sub> alkenyloxy, C<sub>1</sub>-C<sub>8</sub> alkynyloxy, C<sub>2</sub>-C<sub>12</sub> alkoxyalkyl, C<sub>2</sub>-C<sub>12</sub> alkoxyalkyloxy, C<sub>2</sub>-C<sub>12</sub> alkylcarbonyl, C<sub>2</sub>-C<sub>12</sub> alkylcarbonylamino, C<sub>2</sub>-C<sub>12</sub> alkoxyamino, C<sub>2</sub>-C<sub>12</sub> alkoxyaminocarbonyl, C<sub>2</sub>-C<sub>12</sub> alkylamino, C<sub>1</sub>-C<sub>8</sub> alkylthio, C<sub>2</sub>-C<sub>12</sub> alkylthiocarbonyl, C<sub>1</sub>-C<sub>8</sub> alkylsulfinyl, C<sub>1</sub>-C<sub>8</sub> alkylsulfonyl, C<sub>2</sub>-C<sub>8</sub> haloalkoxy, C<sub>1</sub>-C<sub>8</sub> haloalkylsulfonyl, C<sub>2</sub>-C<sub>8</sub> haloalkyl, C<sub>1</sub>-C<sub>8</sub> hydroxyalkyl, -C(O)O(C<sub>1</sub>-C<sub>8</sub> alkyl), -(CH<sub>2</sub>)<sub>n</sub>-O-(C<sub>1</sub>-C<sub>8</sub> alkyl), benzyloxy, phenoxy, phenylthio, (-CONHSO<sub>2</sub>R), -CHO, amino, amidino, bromo, carbamyl, carboxyl, carbalkoxy, -(CH<sub>2</sub>)<sub>n</sub>-CO<sub>2</sub>H, chloro, cyano, cyanoguanidiny, fluoro, guanidino, hydrazide, hydrazino, hydrazido, hydroxy, hydroxyamino, iodo, nitro, phosphono, -SO<sub>3</sub>H, thioacetal, thiocarbonyl, and C<sub>1</sub>-C<sub>8</sub> carbonyl; where n is from 1 to 8; or

(c) is the group -(L<sub>1</sub>)-R<sub>81</sub>; where, -(L<sub>1</sub>)- is a divalent linking group having the formula;



where,


R<sub>84</sub> and R<sub>85</sub> are each independently selected from hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl, aryl, C<sub>1</sub>-C<sub>10</sub> alkaryl, C<sub>1</sub>-C<sub>10</sub> aralkyl, carboxy, carbalkoxy, and halo; p is 1 to 5,

Z is a bond, -(CH<sub>2</sub>)-, -O-, -N(C<sub>1</sub>-C<sub>10</sub> alkyl)-, -NH-, or -S-; and

where  $R_{81}$  is a group selected from (a) or (b);





$R_{12}$  is hydrogen, halo,  $C_1$ - $C_3$  alkyl,  $C_3$ - $C_4$  cycloalkyl,  $C_3$ - $C_4$  cycloalkenyl,  $-O-(C_1-C_2 \text{ alkyl})$ , or  $-S-(C_1-C_2 \text{ alkyl})$ ;

$R_{14}$  is selected from hydrogen, a non-interfering substituent, or the group,  $-(L_a)-(\text{acidic group})$ , wherein  
 5 the acid linker  $-(L_a)-$  has an acid linker length of 2 or 3 atoms and is represented by the formula;








where Q is selected from the group  $-(CH_2)-$ ,  $-O-$ ,  $-NH-$ , and  $-S-$ ;  $R_{84}$  and  $R_{85}$  are each independently selected from hydrogen,  $C_1$ - $C_{10}$  alkyl, aryl,  $C_1$ - $C_{10}$  alkaryl,  $C_1$ - $C_{10}$  aralkyl, hydroxy, and halo; and the acidic group is selected from

-5-tetrazolyl,  
 $-SO_3H$ ,












where  $n$  is 1 to 8,  $R_{89}$  is a metal or  $C_1$ - $C_{10}$  alkyl, and  $R_{99}$  is hydrogen or  $C_1$ - $C_{10}$  alkyl;






$R_{15}$  is selected from hydrogen, a non-interfering substituent, or the group,  $-(L_a)$ -(acidic group), wherein the acid linker  $-(L_a)$ - has an acid linker length of 3 to 8 atoms and the acid linker group,  $-(L_a)$ - is;



where  $r$  is a number from 1 to 7,  $s$  is 0 or 1, and  $Q$  is selected from the group  $-(\text{CH}_2)-$ ,  $-\text{O}-$ ,  $-\text{NH}-$ , and  $-\text{S}-$ ; and  $\text{R}_{84}$  and  $\text{R}_{85}$  are each independently selected from hydrogen,  $\text{C}_1$ - $\text{C}_{10}$  alkyl, aryl,  $\text{C}_1$ - $\text{C}_{10}$  alkaryl,  $\text{C}_1$ - $\text{C}_{10}$  aralkyl, carboxy, carbalkoxy, and halo; and the acidic group is selected from

-5-tetrazolyl,  
- $\text{SO}_3\text{H}$ ,






where  $n$  is 1 to 8,  $R_{89}$  is a metal or  $C_1$ - $C_{10}$  alkyl, and  $R_{99}$  is hydrogen or  $C_1$ - $C_{10}$  alkyl; provided that at least one of  $R_{14}$  or  $R_{15}$  must be the group,  $-(L_a)$ -(acidic group);

$R_{16}$ , and  $R_{17}$  are each independently selected from hydrogen, non-interfering substituents, selected from the group consisting of  $C_1$ - $C_8$  alkyl,  $C_1$ - $C_8$  alkenyl,  $C_1$ - $C_8$  alkynyl,  $C_7$ - $C_{12}$  aralkyl,  $C_7$ - $C_{12}$  alkaryl,  $C_3$ - $C_8$  cycloalkyl,  $C_3$ - $C_8$  cycloalkenyl, phenyl, tolulyl, xylenyl, biphenyl,  $C_1$ - $C_8$  alkoxy,  $C_1$ - $C_8$  alkenyloxy,  $C_1$ - $C_8$  alkynyloxy,  $C_2$ - $C_{12}$  alkoxyalkyl,  $C_2$ - $C_{12}$  alkoxyalkyloxy,  $C_2$ - $C_{12}$  alkylcarbonyl,  $C_2$ - $C_{12}$  alkylcarbonylamino,  $C_2$ - $C_{12}$  alkoxyamino,  $C_2$ - $C_{12}$  alkoxyaminocarbonyl,  $C_1$ - $C_{12}$  alkylamino,  $C_1$ - $C_8$  alkylthio,  $C_2$ - $C_{12}$  alkylthiocarbonyl,  $C_1$ - $C_8$  alkylsulfinyl,  $C_1$ - $C_8$  alkylsulfonyl,  $C_2$ - $C_8$  haloalkoxy,  $C_1$ - $C_8$  haloalkylsulfonyl,  $C_2$ - $C_8$  haloalkyl,  $C_1$ - $C_8$  hydroxyalkyl,  $-C(O)O(C_1$ - $C_8$  alkyl),  $-(CH_2)_n-O-(C_1$ - $C_8$  alkyl), benzyloxy, phenoxy, phenylthio,  $-(CONHSO_2R)$ ,  $-CHO$ , amino, amidino, bromo, carbamyl, carboxyl, carbalkoxy,  $-(CH_2)_n-CO_2H$ , chloro, cyano, cyanoguanidiny, fluoro, guanidino, hydrazide, hydrazino, hydrazido, hydroxy, hydroxyamino, iodo, nitro, phosphono,  $-SO_3H$ , thioacetal, thiocarbonyl, and  $C_1$ - $C_8$  carbonyl; where  $n$  is from 1 to 8.

A preferred class of compounds according to this invention are the compounds represented by the formula (II) where both  $X$ 's are oxygen.


Another preferred class of compounds according to this invention are the compounds represented by formula (II) where the acid linker,  $-(L_a)$ -, for  $R_{15}$  is selected from the groups;

5




10

15



20


25



30


35

40





45


50



55




and




wherein  $\text{R}_{84}$  and  $\text{R}_{85}$  are each independently selected from hydrogen,  $\text{C}_1$ - $\text{C}_{10}$  alkyl, aryl,  $\text{C}_1$ - $\text{C}_{10}$  alkaryl,  $\text{C}_1$ - $\text{C}_{10}$  aralkyl, carboxy, carbalkoxy, and halo.

Preferred compounds of the invention are also those having the general formula (III);




wherein;


$\text{R}_{21}$  is the group  $-(\text{L}_2)-\text{R}_{81}$ ; where,  $-(\text{L}_2)-$  is a divalent linking group having the formula;



p is 1 to 5,  
and  $R_{81}$  is a group selected from (a) or (b);  
where;  
(a) is selected from the group consisting of




and




where  $R_{10}$  is a radical independently selected from halo,  $\text{C}_1\text{--C}_{10}$  alkyl,  $\text{C}_1\text{--C}_{10}$  alkoxy,  $\text{--S--}(\text{C}_1\text{--C}_{10}$  alkyl), and  $\text{C}_1\text{--C}_{10}$  haloalkyl and t is a number from 0 to 5; and


(b) is a member of (a) substituted with one or more independently selected non-interfering substituents selected from the group consisting of  $\text{C}_1\text{--C}_6$  alkyl,  $\text{C}_1\text{--C}_6$  alkoxy,  $\text{C}_2\text{--C}_6$  haloalkoxy,  $\text{C}_2\text{--C}_6$  haloalkyl, bromo, chloro, fluoro, or iodo;  $R_{24}$  is selected from hydrogen,  $\text{C}_1\text{--C}_6$  alkyl,  $\text{C}_1\text{--C}_6$  alkoxy,  $\text{C}_2\text{--C}_6$  haloalkoxy,  $\text{C}_2\text{--C}_6$  haloalkyl, bromo, chloro, fluoro, or iodo, or the group,  $\text{--(L}_a\text{)--(acidic group)}$ , wherein the acid linker  $\text{--(L}_a\text{)--}$  has an acid linker length of 2 or 3 atoms and is represented by the formula;




where Q is selected from the group  $\text{--(CH}_2\text{)--}$ ,  $\text{--O--}$ ,  $\text{--NH--}$ , and  $\text{--S--}$ ;  $R_{84}$  and  $R_{85}$  are each independently selected from hydrogen,  $\text{C}_1\text{--C}_{10}$  alkyl, aryl,  $\text{C}_1\text{--C}_{10}$  alkaryl,  $\text{C}_1\text{--C}_{10}$  aralkyl, hydroxy, and halo; and the acidic group is selected from



$R_{25}$  is selected from hydrogen,  $\text{C}_1\text{--C}_6$  alkyl,  $\text{C}_1\text{--C}_6$  alkoxy,  $\text{C}_2\text{--C}_6$  haloalkoxy,  $\text{C}_2\text{--C}_6$  haloalkyl, bromo, chloro, fluoro, or iodo, or the group,  $\text{--(L}_a\text{)--(acidic group)}$ , wherein the acid linker  $\text{--(L}_a\text{)--}$  has an acid linker length of 3 to 8 atoms and the acid linker group,  $\text{--(L}_a\text{)--}$  is;



where  $r$  is a number from 1 to 7,  $s$  is 0 or 1, and  $Q$  is selected from the group  $-(\text{CH}_2)-$ ,  $-\text{O}-$ ,  $-\text{NH}-$ , and  $-\text{S}-$ ; and  $\text{R}_{84}$  and  $\text{R}_{85}$  are each independently selected from hydrogen,  $\text{C}_1$ - $\text{C}_{10}$  alkyl, aryl,  $\text{C}_1$ - $\text{C}_{10}$  alkaryl,  $\text{C}_1$ - $\text{C}_{10}$  aralkyl, carboxy, carbalkoxy, and halo; and the acidic group is selected from




provided that at least one of  $\text{R}_{24}$  or  $\text{R}_{25}$  must be the group,  $-(\text{L}_a)$ -(acidic group);

$\text{R}_{26}$ , and  $\text{R}_{27}$  are each independently selected from hydrogen, or  $\text{C}_1$ - $\text{C}_6$  alkyl,  $\text{C}_1$ - $\text{C}_6$  alkoxy,  $\text{C}_2$ - $\text{C}_6$  haloalkoxy,  $\text{C}_2$ - $\text{C}_6$  haloalkyl, bromo, chloro, fluoro, or iodo. Most preferred are compounds of formula III wherein only one of  $\text{R}_{24}$  or  $\text{R}_{25}$  are  $-(\text{L}_a)$ -(acidic group),  $\text{R}_{26}$  and/or  $\text{R}_{27}$  are hydrogen, and the acidic group is carboxyl.


Specific preferred compounds and all pharmaceutically acceptable salts, solvates and prodrug derivatives thereof which are illustrative of the compounds of the invention include the following:

- (A) [[3-(2-Amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid,
- (B) dl-2-[[3-(2-Amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]propanoic acid,
- (C) [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid,
- (D) [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-3-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid,
- (E) [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-4-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid,
- (F) [[3-(2-Amino-1,2-dioxoethyl)-1-[(2,6-dichlorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid
- (G) [[3-(2-Amino-1,2-dioxoethyl)-1-[4(fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid,
- (H) [[3-(2-Amino-1,2-dioxoethyl)-2-methyl-1-[(1-naphthalenyl)methyl]-1H-indol-4-yl]oxy]acetic acid,
- (I) [[3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid,
- (J) [[3-(2-Amino-1,2-dioxoethyl)-1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]acetic acid,
- (K) [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-ethyl-1H-indol-4-yl]oxy]acetic acid,
- (L) [[3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-propyl-1H-indol-4-yl]oxy]acetic acid,
- (M) [[3-(2-Amino-1,2-dioxoethyl)-2-cyclopropyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid,
- (N) [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-cyclopropyl-1H-indol-4-yl]oxy]acetic acid,
- (O) 4-[[3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-5-yl]oxy]butanoic acid, and
- (P) mixtures of (A) thru (O) in any combination.

Most preferred are 1H-indole-3-glyoxylamides selected from the formulae:



or



45 The salts of the above 1H-indole-3-glyoxylamide compounds represented by formulae (I) and (II) and named compounds (A) thru (P) are an additional aspect of the invention. In those instances where the compounds of the invention possess acidic or basic functional groups various salts may be formed which are more water soluble and physiologically suitable than the parent compound. Representative pharmaceutically acceptable salts, include but are not limited to, the alkali and alkaline earth salts such as lithium, sodium, potassium, calcium, magnesium, aluminum and the like. Salts are conveniently prepared from the free acid by treating the acid in solution with a base or by exposing the acid to an ion exchange resin.

50 Included within the definition of pharmaceutically acceptable salts are the relatively non-toxic, inorganic and organic base addition salts of compounds of the present invention, for example, ammonium, quaternary ammonium, and amine cations, derived from nitrogenous bases of sufficient basicity to form salts with the compounds of this invention (see, for example, S. M. Berge, *et al.*, "Pharmaceutical Salts," *J. Phar. Sci.*, 66: 1-19 (1977)). Moreover, the basic group(s) of the compound of the invention may be reacted with suitable organic or inorganic acids to form salts such as acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, camsylate, carbonate, chloride, clavulanate, citrate, chloride, edetate, edisylate, es-




tolate, esylate, fluoride, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, bromide, chloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, malseate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, oleate, oxalate, palmitate, pantothenate, phosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, tannate, tartrate, tosylate, trifluoroacetate, trifluoromethane sulfonate, and valerate.

Certain compounds of the invention may possess one or more chiral centers and may thus exist in optically active forms. Likewise, when the compounds contain an alkenyl or alkenylene group there exists the possibility of cis- and trans- isomeric forms of the compounds. The R- and S-isomers and mixtures thereof, including racemic mixtures as well as mixtures of cis- and trans- isomers, are contemplated by this invention. Additional asymmetric carbon atoms can be present in a substituent group such as an alkyl group. All such isomers as well as the mixtures thereof are intended to be included in the invention. If a particular stereoisomer is desired, it can be prepared by methods well known in the art by using stereospecific reactions with starting materials which contain the asymmetric centers and are already resolved or, alternatively by methods which lead to mixtures of the stereoisomers and subsequent resolution by known methods.

Prodrugs are derivatives of the compounds of the invention which have chemically or metabolically cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention which are pharmaceutically active in vivo. Derivatives of the compounds of this invention have activity in both their acid and base derivative forms, but the acid derivative form often offers advantages of solubility, tissue compatibility, or delayed release in a mammalian organism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acidic compound with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a suitable amine. Simple aliphatic or aromatic esters derived from acidic groups pendent on the compounds of this invention are preferred prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy) alkyl esters or ((alkoxycarbonyl)oxy)alkyl esters.

The synthesis of the 1H-indole-3-glyoxylamides of the invention (for example, formula I) can be accomplished by well known methods as recorded in the chemical literature. Those procedures useful for the syntheses of the compounds of the invention are illustrated herein and outlined in the following reaction schemes 1 through 6.


Scheme 1



To obtain the glyoxylamides substituted in the 4-position with an acidic function through an oxygen atom, the reactions outlined in scheme 1 are used (for conversions 1 thru 5, see ref. Robin D. Clark, Joseph M. Muchowski, Lawrence E. Fisher, Lee A. Flippin, David B. Repke, Michel Souchet, *Synthesis*, 1991, 871-878, the disclosures of which are incorporated herein by reference). The ortho-nitrotoluene, 1, is readily reduced to the 2-methylaniline, 2, using Pd/C as catalyst. The reduction can be carried out in ethanol or tetrahydrofuran (THF) or a combination of both, using a low pressure of hydrogen. The aniline, 2, on heating with di-tert-butyl dicar-

bonate in THF at reflux temperature is converted to the N-tert-butylcarbonyl derivative, 3, in good yield. The dilithium salt of the dianion of 3 is generated at -40 to -20°C in THF using sec-butyl lithium and reacted with the appropriately substituted N-methoxy-N-methylalkanamide. This product, 4, may be purified by crystallization from hexane, or reacted directly with trifluoroacetic acid in methylene chloride to give the 1,3-unsubstituted indole 5. The 1,3-unsubstituted indole 5 is reacted with sodium hydride in dimethylformamide at room temperature (20-25°C) for 0.5-1.0 hour. The resulting sodium salt of 5 is treated with an equivalent of arylmethyl halide and the mixture stirred at a temperature range of 0-100°C, usually at ambient room temperature, for a period of 4 to 36 hours to give the 1-arylmethylindole, 6. This indole, 6, is O-demethylated by stirring with boron tribromide in methylene chloride for approximately 5 hours (see ref. Tsung-Ying Shem and Charles A Winter, *Adv. Drug Res.*, 1977, 12, 176, the disclosure of which is incorporated herein by reference). The 4-hydroxyindole, 7, is alkylated with an alpha bromoalkanoic acid ester in dimethylformamide (DMF) using sodium hydride as a base, with reactions conditions similar to that described for the conversion of 5 to 6. The  $\alpha$ -[(indol-4-yl)oxy]alkanoic acid ester, 8, is reacted with oxalyl chloride in methylene chloride to give 9, which is not purified but reacted directly with ammonia to give the glyoxamide 10. This product is hydrolyzed using 1N sodium hydroxide in MeOH. The final glyoxylamide, 11, is isolated either as the free carboxylic acid or as its sodium salt or in both forms.


Scheme 2



To synthesize the glyoxylamides substituted on the indole ring in the 5-position with an oxybutanoic acid and in the 2-position with an alkyl group, the reactions outlined in Scheme 2 are used. The 1,3-unsubstituted


indoles, 12, are made by the same methods described in Scheme 1 to make 5. When 12 in a mixture of DMF and THF was treated first with NaH/mineral oil and then an arylmethyl halide, there is obtained in good yield, the 1-arylmethylindole, 13. This indole, 13, in methylene chloride is reacted with oxalyl chloride and the mixture added directly to THF saturated with ammonia to give the 5-methoxy glyoxamide 15. The 5-methoxy derivative was O-demethylated to the 5-hydroxy compound, 16 by stirring with boron tribromide in methylene chloride. This product is reacted with NaH/mineral oil and gamma-bromobutyric acid, t-butyl ester as described above to give the intermediate 17 that can easily be converted to the carboxylic product, 18, by stirring with trifluoroacetic acid in methylene chloride.

Scheme 3



For the glyoxylamides substituted in the 5-position with oxybutanoic acid and in the 2-position with hydrogen, the commercially available indole, 19 was converted thru the series of reactions outlined in Scheme 3 to the glyoxylamide 24 using reaction conditions similar to that described in Scheme 1.


Scheme 4



To obtain glyoxylamides substituted in the 4-position with an acidic function through an oxygen atom and in the 2-position with chloro, methoxy or methylthio, the reactions outlined in Scheme 4 can be used. The 2-

oxindole 25 can be converted to the 4-oxyester 27 by methods described in Scheme 1. This intermediate on treatment with oxalyl chloride followed by ammonia gives the glyoxamide 29. Alkylation with benzyl bromide and sodium hydride followed by hydrolysis, would give the 2-chloro acid derivative, 31. Utilizing the intermediate 30, the 2-chloro substituent could be replaced by methylmercaptan or methanol to give the 2-methylthio and 2-methoxy derivatives, 34 and 35.

Scheme 5



To obtain the glyoxylamides where the carboxyl group in the four position is connected through a nitrogen atom, the reaction sequence in Scheme 5 can be used. The nitro indole (36) (obtained by the procedure outlined in Tetrahedron 46(17) 6085-6112 (1990) by Jan Bergman and Peter Sand, the disclosure of which is incorporated herein by reference) can be alkylated with an arylmethyl bromide using NaH as base to give (37). Treatment of (37) with oxalyl chloride and then ammonia gives the glyoxylamide (38). Reduction of the nitro group of (38) with hydrogen using Pt/BaSO<sub>4</sub> as catalyst and subsequent alkylation with a 2-bromoacetate using NaHCO<sub>3</sub> as base gives (40). Basic hydrolysis using dilute NaOH gives the product (41).

Scheme 6

5

10

15

20

25

30


35


40

45

50

55





To obtain the glyoxylamides where the carboxyl group in the four position is connected through an all carbon chain, the reactions outlined in Scheme 6 can be used. The benzoic acid 53 is reacted with thionyl chloride to give the corresponding benzoyl chloride which is reacted with 2-amino-2-methyl-1-propanol and then thionyl chloride to give the protected acid 54. The nitro group of the oxazoline is reduced with hydrogen using Pd/C as catalyst and the aniline 55 heated with di-tert-butyl dicarbonate to give the N-tert-butoxycarbonyl derivative 56. This is converted to the indole 57 as reported in Scheme 1 and the indole alkylated with benzyl bromide using NaH and base to give 58. The oxazoline group is converted to an aldehyde by treating with methyl iodide, reducing with sodium borohydride and hydrolyzing with acid. Treating this aldehyde with (carbethoxymethylene)triphenylphosphorane gives the acrylic acid derivative 60. This is reacted with oxalyl chloride and ammonia as previously described and then reduced catalytically using Pd/C to give the glyoxylamide 62. This ester is hydrolyzed to the carboxylic acid derivative 63. Using similar chemistry, the carboxylic acid derivative that is extended by one carbon atom 64 can also be prepared.


1H-indole-3-glyoxylamides described herein are believed to achieve their beneficial therapeutic action principally by direct inhibition of mammalian (including human) sPLA<sub>2</sub>, and not by acting as antagonists for arachidonic acid, nor other active agents below arachidonic acid in the arachidonic acid cascade, such as 5-lipoxygenases, cyclooxygenases, and etc.

The method of the invention for inhibiting sPLA<sub>2</sub> mediated release of fatty acids comprises contacting mammalian sPLA<sub>2</sub> with an therapeutically effective amount of 1H-indole-3-glyoxylamide substituted at the 4 or 5 positions with an acidic derivative, its salt or a prodrug derivative thereof.


A preferred method of the invention comprises contacting sPLA<sub>2</sub> with an therapeutically effective amount of 1H-indole-3-glyoxylamide represented by formulae (I), (II), (III), or compounds (A) thru (O), supra.

A preferred method of the invention also comprises contacting human sPLA<sub>2</sub> with a therapeutically effective amount of 1H-indole-3-glyoxylamide represented by formulae (III) where said glyoxylamide is substituted at the 4 position with an acidic group (or salts or prodrug derivatives thereof). Another aspect of this invention is a method for treating septic shock, adult respiratory distress syndrome, pancreatitis, trauma, bronchial asthma, allergic rhinitis, rheumatoid arthritis, and related diseases which comprises administering to a mammal (including a human) a therapeutically effective dose of 1H-indole-3-glyoxylamides of the invention (see, formula I, II, III or compounds (A) thru (O), supra.) or a pharmaceutically acceptable salt or prodrug derivative thereof. A most preferred method of treating septic shock in humans is to administer a therapeutically effective dose of 1H-indole-3-glyoxylamides selected from the formulae:





or



45 or a pharmaceutically acceptable salt, solvate, or prodrug derivatives thereof.

As previously noted the compounds of this invention are useful for inhibiting sPLA<sub>2</sub> mediated release of fatty acids such as arachidonic acid. By the term, "inhibiting" is meant the prevention or therapeutically significant reduction in release of sPLA<sub>2</sub> initiated fatty acids by the compounds of the invention. By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

50 The specific dose of a compound administered according to this invention to obtain therapeutic or prophylactic effects will, of course, be determined by the particular circumstances surrounding the case, including, for example, the compound administered, the route of administration and the condition being treated. Typical daily doses will contain a non-toxic dosage level of from about 0.01 mg/kg to about 50 mg/kg of body weight of an active compound of this invention.

55 Preferably the pharmaceutical formulation is in unit dosage form. The unit dosage form can be a capsule or tablet itself, or the appropriate number of any of these. The quantity of active ingredient in a unit dose of composition may be varied or adjusted from about 0.1 to about 1000 milligrams or more according to the par-

ticular treatment involved. It may be appreciated that it may be necessary to make routine variations to the dosage depending on the age and condition of the patient. The dosage will also depend on the route of administration.

The compound can be administered by a variety of routes including oral, aerosol, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal.

Pharmaceutical formulations of the invention are prepared by combining (e.g., mixing) a therapeutically effective amount of the 1H-indole-3-glyoxylamides of the invention together with a pharmaceutically acceptable carrier or diluent therefor. The present pharmaceutical formulations are prepared by known procedures using well known and readily available ingredients.

In making the compositions of the present invention, the active ingredient will usually be admixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent, it may be a solid, semi-solid or liquid material which acts as a vehicle, or can be in the form of tablets, pills, powders, lozenges, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), or ointment, containing, for example, up to 10% by weight of the active compound. The compounds of the present invention are preferably formulated prior to administration.

For the pharmaceutical formulations any suitable carrier known in the art can be used. In such a formulation, the carrier may be a solid, liquid, or mixture of a solid and a liquid. For example, for intravenous injection the compounds of the invention may be dissolved in at a concentration of 2 mg/ml in a 4% dextrose/0.5% Na citrate aqueous solution. Solid form formulations include powders, tablets and capsules. A solid carrier can be one or more substances which may also act as flavoring agents, lubricants, solubilisers, suspending agents, binders, tablet disintegrating agents and encapsulating material.

Tablets for oral administration may contain suitable excipients such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, together with disintegrating agents, such as maize, starch, or alginic acid, and/or binding agents, for example, gelatin or acacia, and lubricating agents such as magnesium stearate, stearic acid, or talc.

In powders the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets the active ingredient is mixed with a carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from about 1 to about 99 weight percent of the active ingredient which is the novel compound of this invention. Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, low melting waxes, and cocoa butter.

Sterile liquid form formulations include suspensions, emulsions, syrups and elixirs.

The active ingredient can be dissolved or suspended in a pharmaceutically acceptable carrier, such as sterile water, sterile organic solvent or a mixture of both. The active ingredient can often be dissolved in a suitable organic solvent, for instance aqueous propylene glycol. Other compositions can be made by dispersing the finely divided active ingredient in aqueous starch or sodium carboxymethyl cellulose solution or in a suitable oil.

The following pharmaceutical formulations 1 thru 8 are illustrative only and are not intended to limit the scope of the invention in any way. "Active ingredient", refers to a compound according to Formula (I) or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

#### Formulation 1

Hard gelatin capsules are prepared using the following ingredients:

	Quantity (mg/capsule)
Active ingredient	250
Starch, dried	200
Magnesium stearate	10
Total	460 mg

## Formulation 2

A tablet is prepared using the ingredients below:

	Quantity (mg/tablet)
Active ingredient	250
Cellulose, microcrystalline	400
Silicon dioxide, fumed	10
Stearic acid	5
Total	<u>665 mg</u>

The components are blended and compressed to form tablets each weighing 665 mg

## Formulation 3

An aerosol solution is prepared containing the following components:

	Weight
Active ingredient	0.25
Ethanol	25.75
Propellant 22 (Chlorodifluoromethane)	74.00
Total	<u>100.00</u>

The active compound is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to -30°C and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remainder of the propellant. The valve units are then fitted to the container.

## Formulation 4

Tablets, each containing 60 mg of active ingredient, are made as follows:

Active ingredient	60 mg
Starch	45 mg
Microcrystalline cellulose	35 mg
Polyvinylpyrrolidone (as 10% solution in water)	4 mg
Sodium carboxymethyl starch	4.5 mg
Magnesium stearate	0.5 mg
Talc	1 mg
Total	<u>150 mg</u>

The active ingredient, starch and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The aqueous solution containing polyvinylpyrrolidone is mixed with the resultant powder, and the mixture then is passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50°C and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.

## Formulation 5

Capsules, each containing 80 mg of active ingredient, are made as follows:

Active ingredient	80 mg
Starch	59 mg
Microcrystalline cellulose	59 mg
Magnesium stearate	2 mg
Total	<u>200 mg</u>

The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 200 mg quantities.

## Formulation 6

Suppositories, each containing 225 mg of active ingredient, are made as follows:

Active ingredient	225 mg
Saturated fatty acid glycerides	2,000 mg
Total	<u>2,225 mg</u>

The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool.

## Formulation 7

Suspensions, each containing 50 mg of active ingredient per 5 ml dose, are made as follows:

Active ingredient	50 mg
Sodium carboxymethyl cellulose	50 mg
Syrup	1.25 ml
Benzoic acid solution	0.10 ml
Flavor	q.v.
Color	q.v.
Purified water to total	5 ml

The active ingredient is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color are diluted with a portion of the water and added, with stirring. Sufficient water is then added to produce the required volume.

## Formulation 8

An intravenous formulation may be prepared as follows:

Active ingredient	100 mg
Isotonic saline	1,000 ml


The solution of the above ingredients generally is administered intravenously to a subject at a rate of 1 ml per

minute.

All of the products of the Examples described below as well as intermediates used in the following procedures showed satisfactory nmr and ir spectra. They also had the correct mass spectral values.

### 5 Example 1

Preparation of [[3-(2-Amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid, a compound represented by the formula:



#### Part A. Preparation of N-tert-butoxycarbonyl-3-methoxy-2-methylaniline.

A solution of 44.4g (344 mmol) of 3-methoxy-2-methylaniline and 75g (344 mmol) of di-tert-butyl dicarbonate in 400 mL of THF was heated to maintain reflux for 4 hours. After concentrating at reduced pressure, the residue was taken up in ethyl acetate, washed with 1N citric acid, water and dried (MgSO<sub>4</sub>). After removing the solvent at reduced pressure, the residue was crystallized from hexane to give 64.5g (84% yield) of N-tert-butoxycarbonyl-3-methoxy-2-methylaniline, mp, 56-57°C.

Analysis for C <sub>13</sub> H <sub>19</sub> NO <sub>3</sub> :			
Calculated:	C, 65.80;	H, 8.07;	N, 5.90
Found:	C, 63.32;	H, 7.83;	N, 5.56.

#### Part B. Preparation of 4-Methoxy-2-methyl-1H-indole.

A solution of 280 mL (0.36 mol) of 1.3M sec-butyl lithium in cyclohexane was added slowly to N-tert-butoxycarbonyl-3-methoxy-2-methylaniline (43g, 0.18 mol) in 300 mL of THF keeping the temperature below -40°C with a dry ice-ethanol bath. The bath was removed and the temperature allowed to rise to -20°C and then the bath replaced. After the temperature had cooled to -60°C, 18.5g (0.18 mol) of N-methoxy-N-methylglyoxylamide in an equal volume of THF was added dropwise. The reaction mixture was stirred 1 hour, the cooling bath removed and stirred an additional 1 hour. It was then poured into a mixture of 600 mL of ether and 600 mL of 1N HCl. The organic layer was separated, washed with water, dried over MgSO<sub>4</sub>, and concentrated at reduced pressure to give 39.5g of a mixture of 1-[2-(tert-butoxycarbonylamino)-6-methoxyphenyl]-2-propanone and starting anilide. This mixture was dissolved in 100 mL of methylene chloride and 40 mL of trifluoroacetic acid and stirred for a total of 26 hours. The mixture was washed with water, dried (MgSO<sub>4</sub>) and concentrated at reduced pressure. The residue was chromatographed on silica gel eluting with 20% EtOAc/hexane to give on crystallization from CH<sub>2</sub>Cl<sub>2</sub>/hexane 13.9g of 4-methoxy-2-methyl-1H-indole, mp, 80-86°C.

Analysis for  $C_{10}H_{11}NO$ :

Calculated:	C, 74.51;	H, 6.88;	N, 8.69
Found:	C, 74.41;	H, 7.08;	N, 8.47.

**Part C.** Preparation of 4-Methoxy-2-methyl-1-(phenylmethyl)-1H-indole.

4-Methoxy-2-methyl-1H-indole (1g, 6.2 mmol) was added to 248 mg (6.2 mmol) of 60% sodium hydride/mineral oil (washed with hexane before adding DMF) in 15 mL of DMF and after stirring for 0.5 hour, 0.74 mL (6.2 mmol) of benzyl bromide was added. The mixture was stirred at room temperature for 18 hours, diluted with water and extracted with ethyl acetate. The ethyl acetate solution was washed with brine, dried ( $MgSO_4$ ) and after concentrating at reduced pressure, the residue was chromatographed on silica gel eluting with 20% EtOAc/hexane to give 1.3g (84% yield) of 4-methoxy-2-methyl-1-(phenylmethyl)-1H-indole, melting at 96-116°C.

Analyses for  $C_{17}H_{17}NO$ :

Calculated:	C, 81.24;	H, 6.82;	N, 5.57
Found:	C, 81.33;	H, 6.74;	N, 5.29.

**Part D.** Preparation of 4-Hydroxy-2-methyl-1-(phenylmethyl)-1H-indole.

A solution of 1.25g (5 mmol) of 4-methoxy-2-methyl-1-(phenylmethyl)-1H-indole and 20 mL of 1M  $BBr_3/CH_2Cl_2$  in 50 mL of methylene chloride was stirred at room temperature for 5 hours and concentrated at reduced pressure. The residue was dissolved in ethyl acetate, washed with brine and dried ( $MgSO_4$ ). After concentrating at reduced pressure, the residue was chromatographed on silica gel eluting with 20% EtOAc/hexane to give 577mg (49% yield) of 4-hydroxy-2-methyl-1-(phenylmethyl)-1H-indole, 125-127°C.

Analyses for  $C_{16}H_{15}NO$ :

Calculated:	C, 80.98;	H, 6.37;	N, 5.90
Found:	C, 80.76;	H, 6.26;	N, 5.80.

**Part E.** Preparation of [[2-Methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester.

4-Hydroxy-2-methyl-1-(phenylmethyl)-1H-indole (530mg, 2.2 mmol) was added to 88mg (2.2 mmol) of 60% NaH/mineral oil in 20 mL of DMF and the mixture stirred for 0.67 hours. Then, 0.21 mL (2.2 mmol) of methyl bromoacetate was added and stirring maintained for 17 hours. The mixture was diluted with water and extracted with ethyl acetate. The ethyl acetate solution was washed with brine, dried ( $MgSO_4$ ), and concentrated at reduced pressure. The residue was chromatographed on silica gel eluting with 20% EtOAc/hexane to give 597mg (88% yield) of [[2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester, 140-143°C.

Analyses for  $C_{19}H_{19}NO_3$ :

Calculated:	C, 73.77;	H, 6.19;	N, 4.53
Found:	C, 74.01;	H, 6.23;	N, 4.32.

**Part F.** Preparation of [[3-(2-Amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester.

Oxalyl chloride (0.16 mL, 1.9 mmol) was added to 582mg (1.9 mmol) of [[2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester in 10 mL of methylene chloride and the mixture stirred for 1.5 hours. The mixture was concentrated at reduced pressure and residue taken up in 10 mL of methylene chloride. Anhydrous ammonia was bubbled in for 0.25 hours, the mixture stirred for 1.5 hours and evaporated at reduced pressure. The residue was stirred with 20 mL of ethyl acetate and the mixture filtered. The filtrate was concentrated to give 672mg of a mixture of [[3-(2-amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid, methyl ester and ammonium chloride, mp 202-215°C.

**Part G.** Preparation of [[3-(2-Amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid.


A mixture of 660mg (1.7 mmol) of [[3-(2-amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester and 10 mL of 1N NaOH in 30 mL of methanol was heated to maintain reflux for 1 hour, cooled to room temperature and stirred for 0.5 hour. The mixture was concentrated at reduced pressure and the residue taken up in EtOAc/water. The aqueous layer was separated, made acidic to pH 2-3 with 1N HCl and extracted with EtOAc. On concentrating the EtOAc solution, 431mg (69% yield) of [[3-(2-amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid crystallized, melting at 218-220°C.

Analyses for  $C_{20}H_{18}N_2O_5$ :

Calculated:	C, 65.57;	H, 4.95;	N, 7.65
Found:	C, 63.31;	H, 4.79;	N, 6.91.

### Example 2

Preparation of dl-2-[[3-(2-Amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]propanoic acid, a compound represented by the formula:



**Part A.** Preparation of dl-2-[[2-Methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]propanoic acid methyl ester.

4-Hydroxy-2-methyl-1-(phenylmethyl)-1H-indole (483mg, 2.0 mmol) was reacted with 82mg (2.0 mmol) of 60% NaH/mineral oil in 20 mL of DMF and then with 0.22 mL (2.0 mmol) of dl-methyl 2-bromopropionate as described in Example 1, Part E to give after chromatography on silica gel eluting with 20% EtOAc/hexane 480mg (74% yield) of dl-2-[[2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]propanoic acid methyl ester.

**Part B.** Preparation of dl-2-[[3-(2-Amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]propanoic acid, methyl ester.

Oxalyl chloride (0.16 mL, 1.9 mmol) was reacted with 480mg (1.5 mmol) of dl-2-[[2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]propanoic acid methyl ester and then reacted with anhydrous ammonia as in Example 1, Part F and the reaction product was dissolved in EtOAc, washed with water, dried ( $MgSO_4$ ) and concentrated. The residue was chromatographed on silica gel (eluted with EtOAc) to give 531mg (90% yield) of dl-2-[[3-(2-amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]propanoic acid, methyl ester, melting at approximately 175°C.

Analyses for  $C_{22}H_{22}N_2O_5$ :

Calculated:	C, 66.99;	H, 5.62;	N, 7.10
Found:	C, 67.28;	H, 5.59;	N, 7.03.

**Part C.** Preparation of dl-2-[[3-(2-Amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-


yl]oxy]propanoic acid.

A mixture of 521mg (1.3 mmol) of dl-2-[[3-(2-amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]propanoic acid methyl ester and 10 mL of 1N NaOH in 30 mL of methanol was heated to maintain reflux for 0.17 hours, cooled to room temperature and stirred for 0.5 hour. The mixture was concentrated at reduced pressure and the residue taken up in EtOAc/water. The aqueous layer was separated, made acidic to pH 2-3 with 1N HCl and extracted with EtOAc. The EtOAc solution was concentrated at reduced pressure and the residue stirred with a EtOAc-ether mixture. The insoluble material was filtered to give 246mg (50% yield) of dl-2-[[3-(2-amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]propanoic acid, mp, 201-204°C.

Analyses for C <sub>21</sub> H <sub>20</sub> N <sub>2</sub> O <sub>5</sub> :			
Calculated:	C, 66.31;	H, 5.30;	N, 7.36
Found:	C, 65.63;	H, 5.61;	N, 7.03.

### Example 3

Preparation of [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid, a compound represented by the formula:



#### Part A. Preparation of 1-([1,1'-Biphenyl]-2-ylmethyl)-4-methoxy-2-methyl-1H-indole.

Using the procedure described in Example 1, Part C, 1g (6.2 mmol) of 4-methoxy-2-methyl-1H-indole was reacted with 248mg (6.2 mmol) of 60% NaH/mineral oil and then 1.1 mL (6.2 mmol) of 2-(bromomethyl)biphenyl to give after chromatography on silica (eluting with 17% EtOAc/hexane) 1.63g (80% yield) of 1-([1,1'-biphenyl]-2-ylmethyl)-4-methoxy-2-methyl-1H-indole as an oil.

Analyses for C <sub>23</sub> H <sub>21</sub> NO:			
Calculated:	C, 84.37;	H, 6.46;	N, 4.28
Found:	C, 84.11;	H, 5.66;	N, 3.83.

#### Part B. Preparation of 1-([1,1'-Biphenyl]-2-ylmethyl)-4-hydroxy-2-methyl-1H-indole.

By the method used in Example 1, Part D, 1.6g (4.9 mmol) of 1-([1,1'-biphenyl]-2-ylmethyl)-4-methoxy-2-



methyl-1H-indole was O-demethylated by treating it with 20 mL of 1M BBr<sub>3</sub>/CH<sub>2</sub>Cl<sub>2</sub>. The crude product was chromatographed on silica gel and eluted with 20% EtOAc/hexane to give 841mg (55% yield) of 1-([1,1'-biphenyl]-2-ylmethyl)-4-hydroxy-2-methyl-1H-indole.

Analyses for C<sub>22</sub>H<sub>19</sub>NO:

Calculated:	C, 84.32;	H, 6.11;	N, 4.47
Found:	C, 84.59;	H, 6.33;	N, 4.75.

**Part C.** Preparation of [[1-([1,1'-Biphenyl]-2-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester. 1-([1,1'-Biphenyl]-2-ylmethyl)-4-hydroxy-2-methyl-1H-indole (767mg, 2.45 mmol) was alkylated by treating with 0.23 mL (2.45 mmol) of methyl bromoacetate and 98mg (2.45 mmol) of 60% NaH/mineral oil in DMF as described in Example 1, Part E. The product was purified by chromatography over silica gel eluting with 20% EtOAc/hexane, to give 730mg(77% yield) of [[1-([1,1'-biphenyl]-2-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester, 99-101°C.

Analyses for C<sub>25</sub>H<sub>23</sub>NO<sub>3</sub>:

Calculated:	C, 77.90;	H, 6.01;	N, 3.63
Found:	C, 78.11;	H, 6.17;	N, 3.74.

**Part D.** Preparation of [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester.

Using the procedure in Example 1, Part F, 715mg (1.9 mmol) of [[1-([1,1'-biphenyl]-2-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester was reacted first with 0.16 mL (1.9 mmol) of oxalyl chloride and then excess ammonia to give a white solid. This was stirred with ethyl acetate and the insoluble material separated and dried to give 660mg of a mixture of [[3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester and ammonium chloride. This mixture melted at 144-148°C.

**Part E.** Preparation of [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid.

A mixture of 648mg (1.4 mmol) of [[3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester in 10 mL of 1N NaOH and 20 mL of MeOH was heated to maintain reflux for 1 hour, cooled to room temperature and stirred 0.5 hour. The mixture was concentrated, the residue stirred with a mixture of EtOAc/water and the solid material that did not dissolve was filtered and dried to give 227mg (35% yield) of [[3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid, sodium salt, mp, >265°C.

Analyses for C<sub>28</sub>H<sub>21</sub>N<sub>2</sub>O<sub>5</sub>Na:

Calculated:	C, 67.24;	H, 4.56;	N, 6.03
Found:	C, 69.38;	H, 4.88;	N, 5.42.


**Part F.** The aqueous layer was separated from the filtrate from above and made acidic to pH 2-3 with 1N HCl. The precipitate was extracted with EtOAc and upon concentrating the EtOAc, 128mg (20% yield) of [[3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid precipitated, mp, 228-231°C.

Analyses for C<sub>28</sub>H<sub>22</sub>N<sub>2</sub>O<sub>5</sub>:

Calculated:	C, 70.58;	H, 5.01;	N, 6.33
Found:	C, 73.12;	H, 5.37;	N, 5.81.

#### Example 4

Preparation of [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-3-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid, a compound represented by the formula:



**Part A.** Preparation of 1-([1,1'-Biphenyl]-3-ylmethyl)-4-methoxy-2-methyl-1H-indole.

Using the method in Example 1, Part C, 805mg (5 mmol) of 4-methoxy-2-methyl-1H-indole was reacted with 200mg (5 mmol) of 60% NaH/mineral and then 1.0g(5 mmol) of 3-(chloromethyl)biphenyl in DMF to give after chromatography on silica gel (eluted with 20% EtOAc/hexane) 1.25g(76% yield) of 1-([1,1'-biphenyl]-3-ylmethyl)-4-methoxy-2-methyl-1H-indole, mp, 127-131°C.

Analyses for  $C_{23}H_{21}NO$ :

Calculated:	C, 84.37;	H, 6.46;	N, 4.27
Found:	C, 83.30;	H, 6.55;	N, 4.07.

**Part B.** Preparation of 1-([1,1'-Biphenyl]-3-ylmethyl)-4-hydroxy-2-methyl-1H-indole.

By the method used in Example 1, Part D, 1.25g (3.8 mmol) of 1-([1,1'-biphenyl]-3-ylmethyl)-4-methoxy-2-methyl-1H-indole was O-demethylated by treating it with 15.2 mL of 1M  $BBr_3/CH_2Cl_2$  to give 1.03g (87% yield) of crude 1-([1,1'-biphenyl]-3-ylmethyl)-4-hydroxy-2-methyl-1H-indole.

**Part C.** Preparation of [[1-([1,1'-Biphenyl]-3-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester.

1-([1,1'-Biphenyl]-3-ylmethyl)-4-hydroxy-2-methyl-1H-indole(1.03g, 3.3 mmol) was alkylated by treating with 0.31 mL (3.3 mmol) of methyl bromoacetate and 132mg (3.3 mmol) of 60% NaH/mineral oil in DMF as described in Example 1, Part E. The product was purified by chromatography over silica gel eluting with 20% EtOAc/hexane, to give 1.0g(79% yield) of [[1-([1,1'-biphenyl]-3-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester, 99-102°C.

Analyses for  $C_{25}H_{23}NO_3$ :

Calculated:	C, 77.90;	H, 6.01;	N, 3.63
Found:	C, 77.61;	H, 6.09;	N, 3.62.

**Part D.** Preparation of [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-3-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester.

Oxalyl chloride (0.23 mL, 2.6 mmol) was added to 1.0g (2.6 mmol) of [[1-([1,1'-biphenyl]-3-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester in 15 mL of methylene chloride and the mixture stirred for 1.3 hours. The mixture was concentrated at reduced pressure, the residue redissolved in 15 mL of methylene chloride and ammonia gas bubbled in for 0.25 hours, stirred for 0.25 hours and concentrated. The residue was stirred with EtOAc/water and the undissolved material filtered to give 300mg of [[3-(2-amino-1,2-dioxoethyl)-1-([1,1'-

biphenyl]-3-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester. The EtOAc layer from the filtrate was separated, washed with brine, dried (MgSO<sub>4</sub>) and concentrated. The residue was chromatographed on silica gel eluting with EtOAc to give an additional 671mg of [[3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-3-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester, mp, 175-179°C. The total combined yield of product was 82%.

Analyses for C<sub>27</sub>H<sub>24</sub>N<sub>2</sub>O<sub>5</sub>:

Calculated: C, 71.04; H, 5.30; N, 6.14

Found: C, 71.30; H, 5.41; N, 6.35.

**Part E.** Preparation of [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-3-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid.

Using the procedure described in Example 2, Part E, 956mg (2.1 mmol) of [[3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-3-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester was hydrolyzed in 10 mL of 1N NaOH and 20 mL of MeOH to give 403mg (41% yield) of [[3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-3-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid, sodium salt, mp, >265°C.

Analyses for C<sub>26</sub>H<sub>21</sub>N<sub>2</sub>O<sub>5</sub>Na:

Calculated: C, 67.24; H, 4.56; N, 6.03

Found: C, 67.20; H, 4.58; N, 6.03.

There was also obtained 346mg (37% yield) of [[3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-3-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid, mp, 236-238°C.


Analyses for C<sub>26</sub>H<sub>22</sub>N<sub>2</sub>O<sub>5</sub>:

Calculated: C, 70.58; H, 5.01; N, 6.33

Found: C, 70.58; H, 5.25; N, 6.11.

### Example 5

Preparation of [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-4-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid, a compound represented by the formula:



**Part A.** Preparation of 1-([1,1'-Biphenyl]-4-ylmethyl)-4-methoxy-2-methyl-1H-indole.

Using the method in Example 1, Part C, 805mg (5 mmol) of 4-methoxy-2-methyl-1H-indole was reacted with 200mg (5 mmol) of 60% NaH/mineral oil and then 1.0g(5 mmol) of 4-(chloromethyl)biphenyl in DMF to give after chromatography on silica gel (eluted with 20% EtOAc/hexane) 1.3g (80% yield) of 1-([1,1'-biphenyl]-4-ylmethyl)-4-methoxy-2-methyl-1H-indole, mp, 118-123°C.

Analyses for C <sub>23</sub> H <sub>21</sub> NO:			
Calculated:	C, 84.37;	H, 6.46;	N, 4.27
Found:	C, 84.66;	H, 6.62;	N, 4.00.

**Part B.** Preparation of 1-([1,1'-Biphenyl]-4-ylmethyl)-4-hydroxy-2-methyl-1H-indole.

By the method used in Example 1, Part D, 1.3g (4.0 mmol) of 1-([1,1'-biphenyl]-4-ylmethyl)-4-methoxy-2-methyl-1H-indole was O-demethylated by treating it with 16 mL of 1M BBr<sub>3</sub>/CH<sub>2</sub>Cl<sub>2</sub> to give 970mg (77% yield) of crude 1-([1,1'-biphenyl]-4-ylmethyl)-4-hydroxy-2-methyl-1H-indole.

**Part C.** [1-([1,1'-Biphenyl]-4-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester.

Using the procedure described in Example 1, Part E, 1-([1,1'-biphenyl]-3-ylmethyl)-4-hydroxy-2-methyl-1H-indole (970mg, 3.1 mmol) was treated with 124mg (3.1 mmol) of 60% NaH/mineral oil and then 0.29 mL (3.1 mmol) of methyl bromoacetate. The product was purified by chromatography over silica gel eluting with 20% EtOAc/hexane, to give 747mg(63% yield) of [1-([1,1'-biphenyl]-4-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester, 164-167°C.

Analyses for C <sub>25</sub> H <sub>23</sub> NO <sub>3</sub> :			
Calculated:	C, 77.90;	H, 6.01;	N, 3.63
Found:	C, 78.83;	H, 6.10;	N, 3.56.

**Part D.** Preparation of [3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-4-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester.

Oxalyl chloride (0.17 mL, 1.9 mmol) was added to 747mg (2.6 mmol) of [1-([1,1'-biphenyl]-4-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester in 15 mL of methylene chloride and the mixture stirred for 1.3 hours. The mixture was concentrated at reduced pressure, the residue redissolved in 15 mL of methylene chloride and ammonia gas bubbled in for 0.25 hours, stirred for 0.25 hours and concentrated. The residue was stirred with EtOAc/water and the undissolved material filtered to give 818mg (94% yield) of [3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-4-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester, 215-217°C.

Analyses for C <sub>27</sub> H <sub>24</sub> N <sub>2</sub> O <sub>6</sub> :			
Calculated:	C, 71.04;	H, 5.30;	N, 6.14
Found:	C, 71.32;	H, 5.43;	N, 6.33.

**Part E.** Preparation of [3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-4-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid.

Using the procedure described in Example 2, Part E, 803mg (1.8 mmol) of [3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-4-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester was hydrolyzed in 10 mL of 1N NaOH and 20 mL of MeOH to give 614mg (74% yield) of [3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-4-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid, sodium salt, mp, >265°C.

Analyses for C <sub>26</sub> H <sub>21</sub> N <sub>2</sub> O <sub>6</sub> Na:			
Calculated:	C, 67.24;	H, 4.56;	N, 6.03
Found:	C, 67.48;	H, 4.62;	N, 6.14.


There was also obtained 35mg(4% yield) of [3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-4-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid, mp, 228-232°C.

Analyses for  $C_{26}H_{22}N_2O_6$ :

Calculated:	C, 70.58;	H, 5.01;	N, 6.33
Found:	C, 70.54;	H, 5.08;	N, 6.14.

**Example 6**

Preparation of 1-[(2-Amino-1,2-dioxoethyl)-1-[(2,6-dichlorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid, a compound represented by the formula:

**Part A. Preparation of 1-[(2,6-Dichlorophenyl)methyl]-4-methoxy-2-methyl-1H-indole.**

4-Methoxy-2-methyl-1H-indole (805mg, 5 mmol) was added to a mixture of 160mg (4 mmol) of 60% sodium hydride/mineral oil (washed with hexane before adding DMF) in 10 mL of DMF and after stirring for 0.67 hours, 782mg (4 mmol) of  $\alpha$ ,2,6-trichlorotoluene was added. The mixture was stirred at room temperature for 5 hours, diluted with water and extracted with ethyl acetate. The ethyl acetate solution was washed with brine, dried ( $MgSO_4$ ) and after concentrating at reduced pressure, the residue was chromatographed on silica gel eluting with 20% EtOAc/hexane to give 1.08g (84% yield) of 1-[(2,6-dichlorophenyl)methyl]-4-methoxy-2-methyl-1H-indole, melting at 154-157°C.

Analyses for  $C_{17}H_{16}Cl_2NO$ :

Calculated:	C, 63.77;	H, 4.72;	N, 4.37
Found:	C, 67.16;	H, 5.14;	N, 4.19.

**Part B. Preparation of 1-[(2,6-Dichlorophenyl)methyl]-4-hydroxy-2-methyl-1H-indole.**

By the method used in Example 1, Part D, 1.08g (3.38 mmol) of 1-[(2,6-dichlorophenyl)methyl]-4-methoxy-2-methyl-1H-indole was O-demethylated by treating it with 13.5 mL of 1M  $BBr_3/CH_2Cl_2$  to give 862mg (83% yield) of 1-[(2,6-dichlorophenyl)methyl]-4-hydroxy-2-methyl-1H-indole, after chromatography on silica gel (eluted with 20% EtOAc/hexane).

Analyses for  $C_{16}H_{13}Cl_2NO$ :

Calculated:	C, 62.76;	H, 4.28;	N, 4.57
Found:	C, 63.03;	H, 4.45;	N, 4.56.

**Part C. Preparation of 1-[(2,6-Dichlorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester.**

Using the procedure described in Example 1, Part E, 1-[(2,6-dichlorophenyl)methyl]-4-hydroxy-2-methyl-1H-indole (862mg, 2.8 mmol) was treated with 112mg (2.8 mmol) of 60% NaH/mineral oil and then 0.27 mL (2.8 mmol) of methyl bromoacetate. The product was purified by chromatography over silica gel eluting with 20% EtOAc/hexane, to give 411mg (39% yield) of [1-[(2,6-dichlorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester, mp, 168-169°C.

Analyses for  $C_{19}H_{17}Cl_2NO_3$ :

Calculated: C, 60.33; H, 4.53; N, 3.70

Found: C, 60.55; H, 4.70; N, 3.75.

**Part D.** Preparation of [3-(2-Amino-1,2-dioxoethyl)-1-[(2,6-dichlorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester.

Oxalyl chloride (0.09 mL, 1.07 mmol) was added to 405mg (1.07 mmol) of [1-[(2,6-dichlorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester in 10 mL of methylene chloride and the mixture stirred for 3.0 hours. The mixture was concentrated at reduced pressure, the residue redissolved in 15 mL of methylene chloride and ammonia gas bubbled in for 0.25 hours, stirred for 0.25 hours and concentrated. The residue was stirred with EtOAc/water. The EtOAc layer was separated, washed with brine, dried ( $MgSO_4$ ) and concentrated. The residue was chromatographed on silica gel eluting with EtOAc to give 426mg (88% yield) of [3-(2-amino-1,2-dioxoethyl)-1-[(2,6-dichlorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester, mp, 200-202°C.

Analyses for  $C_{21}H_{18}Cl_2N_2O_5$ :

Calculated:	C, 56.14;	H, 4.04;	N, 6.24
Found:	C, 56.39;	H, 4.15;	N, 6.45.

**Part E.** Preparation of [3-(2-Amino-1,2-dioxoethyl)-1-[(2,6-dichlorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid.


A mixture of 420mg (0.94 mmol) of [3-(2-amino-1,2-dioxoethyl)-1-[(2,6-dichlorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester, 5 mL of 1N NaOH and 15 mL of MeOH was heated to maintain reflux for 0.17 hours, cooled to room temperature and stirred 0.5 hours. Ethyl acetate and water was added, the aqueous layer separated, made acidic to pH 2-3 with 1N HCl, and the mixture extracted with ethyl acetate two times. The part that was not soluble was filtered. The filtrate was dried ( $MgSO_4$ ) and concentrated. The remaining solid was washed with a small volume of ether/methylene chloride and the insoluble material filtered and combined with the filtered material above to give 351mg (86% yield) of [3-(2-amino-1,2-dioxoethyl)-1-[(2,6-dichlorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid, mp, 236-239°C.

Analyses for  $C_{20}H_{16}Cl_2N_2O_5$ :

Calculated:	C, 55.19;	H, 3.70;	N, 6.44
Found:	C, 55.34;	H, 3.72;	N, 6.35.

#### Example 7

Preparation of [3-(2-Amino-1,2-dioxoethyl)-1-[4(fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid, a compound represented by the formula:



**Part A. Preparation of 1-[(4-Fluorophenyl)methyl]-4-methoxy-2-methyl-1H-indole.**

4-Methoxy-2-methyl-1H-indole (805mg, 5 mmol) was added to a mixture of 200 mg (5 mmol) of 60% sodium hydride/mineral oil (washed with hexane before adding DMF) in 10 mL of DMF and after stirring for 0.5 hours, 0.6 mL (5 mmol) of 4-fluorobenzyl chloride was added. The mixture was stirred at room temperature for 18 hours, diluted with water and extracted with ethyl acetate. The ethyl acetate solution was washed with brine, dried (MgSO<sub>4</sub>) and after concentrating at reduced pressure, the residue was chromatographed on silica gel eluting with 20% EtOAc/hexane to give 1.1g (84% yield) of 1-[(4-fluorophenyl)methyl]-4-methoxy-2-methyl-1H-indole, melting at 104-108°C.

**Analyses for C<sub>17</sub>H<sub>18</sub>FNO:**

Calculated:	C, 75.82;	H, 5.99;	N, 5.20
Found:	C, 73.82;	H, 5.95;	N, 5.01.

**Part B. Preparation of 1-[(4-Fluorophenyl)methyl]-4-hydroxy-2-methyl-1H-indole.**

By the method used in Example 1, Part D, 1.1g (4.1 mmol) of 1-[(4-fluorophenyl)methyl]-4-methoxy-2-methyl-1H-indole was O-demethylated by treating it with 16.4 mL of 1M BBr<sub>3</sub>/CH<sub>2</sub>Cl<sub>2</sub> to give 881mg (84% yield) of crude 1-[(4-fluorophenyl)methyl]-4-hydroxy-2-methyl-1H-indole.

**Part C. Preparation of [[1-[(4-Fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester.**

Using the procedure described in Example 1, Part E, 1-[(4-fluorophenyl)methyl]-4-hydroxy-2-methyl-1H-indole (881mg, 3.45 mmol) was treated with 138mg (3.45 mmol) of 60% NaH/mineral oil and then 0.33 mL (3.45 mmol) of methyl bromoacetate. The product was purified by chromatography over silica gel eluting with 20% EtOAc/hexane, to give 914mg (81% yield) of [[1-[(4-fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester, mp, 92-98°C.

**Analyses for C<sub>19</sub>H<sub>18</sub>FNO<sub>3</sub>:**

Calculated:	C, 69.71;	H, 5.54;	N, 4.28
Found:	C, 70.83;	H, 6.00;	N, 4.08.

**Part D. Preparation of [[3-(2-Amino-1,2-dioxoethyl)-1-[(4-fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester.**

Oxalyl chloride (0.24 mL, 2.6 mmol) was added to 914mg (2.8 mmol) of [[1-[(4-fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester in 15 mL of methylene chloride and the mixture stirred for 1.3 hour. The mixture was concentrated at reduced pressure, the residue redissolved in 15 mL of methylene chloride and ammonia gas bubbled in for 0.25 hours, stirred for 0.25 hours and concentrated. The residue was stirred with EtOAc/water and the undissolved material filtered to give 25mg (4% yield) of [[3-(2-amino-1,2-dioxoethyl)-1-[(4-fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester. The EtOAc layer from the fil-

trate was separated, washed with brine, dried ( $\text{MgSO}_4$ ) and concentrated. The residue was chromatographed on silica gel eluting with EtOAc to give an additional 757mg of [[3-(2-amino-1,2-dioxoethyl)-1-[(4-fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester, mp, 178-180°C. The total combined yield of product was 70%.

Analyses for  $\text{C}_{21}\text{H}_{19}\text{FN}_2\text{O}_5$ :

Calculated:	C, 63.31;	H, 4.81;	N, 7.03
Found:	C, 62.31;	H, 4.78;	N, 6.85.

**Part E.** Preparation of [[3-(2-Amino-1,2-dioxoethyl)-1-[(4-fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid.


A mixture of 767mg (1.9 mmol) of [[3-(2-amino-1,2-dioxoethyl)-1-[(4-fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid methyl ester, 10 mL of 1N NaOH and 30 mL of MeOH was heated to maintain reflux for 0.67 hours, cooled to room temperature and stirred 1 hour. Ethyl acetate and water were added and the aqueous layer separated, made acidic to pH 2-3 with 1N HCl and the mixture extracted with ethyl acetate two times. The combined ethyl acetate extracts were dried ( $\text{MgSO}_4$ ) and concentrated. The remaining solid was washed with a small volume of ethyl acetate to give 593mg (81% yield) of [[3-(2-amino-1,2-dioxoethyl)-1-[(4-fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid, mp, 244-247°C.

Analyses for  $\text{C}_{20}\text{H}_{17}\text{FN}_2\text{O}_5$ :

Calculated:	C, 62.50;	H, 4.46;	N, 7.29
Found:	C, 62.40;	H, 4.57;	N, 7.00.

**Example 8**

Preparation of [[3-(2-Amino-1,2-dioxoethyl)-2-methyl-1-[(1-naphthalenyl)methyl]-1H-indol-4-yl]oxy]acetic acid, a compound represented by the formula:



**Part A.** Preparation of 4-Methoxy-2-methyl-1-[(1-naphthalenyl)methyl]-1H-indole.

4-Methoxy-2-methyl-1H-indole (644mg, 4 mmol) was dissolved in 10 mL of DMF and 160mg (4 mmol) of 60% NaH/mineral oil was added. After 0.67 hours, 707mg (4 mmol) of 1-(chloromethyl)naphthalene was added. After 5 hours, the mixture was diluted with water and extracted twice with ethyl acetate. The combined ethyl



acetate was washed with brine, dried ( $\text{MgSO}_4$ ) and concentrated at reduced pressure. The residue was chromatographed on silica gel and eluted with 20% EtOAc/hexane to give 1.17g (97% yield) of 4-methoxy-2-methyl-1-[(1-naphthalenyl)methyl]-1H-indole.

Analyses for  $\text{C}_{21}\text{H}_{19}\text{NO}$ :

Calculated:	C, 83.69;	H, 6.35;	N, 4.65
Found:	C, 83.71;	H, 6.45;	N, 4.41.

**Part B.** Preparation of 4-Hydroxy-2-methyl-1-[(1-naphthalenyl)methyl]-1H-indole.

By the method used in Example 1, Part D, 1.17g (3.9 mmol) of 4-methoxy-2-methyl-1-[(1-naphthalenyl)methyl]-1H-indole was O-demethylated by treating it with 15.6 mL of 1M  $\text{BBr}_3/\text{CH}_2\text{Cl}_2$  to give a material that was chromatographed on silica gel (eluted with 20% EtOAc/hexane then 50% EtOAc/hexane) to give 796mg (71% yield) of 4-hydroxy-2-methyl-1-[(1-naphthalenyl)methyl]-1H-indole.

**Part C.** Preparation of [[2-Methyl-1-[(1-naphthalenyl)methyl]-1H-indol-4-yl]oxy]acetic acid methyl ester.

Using the procedure described in Example 1, Part E, 4-hydroxy-2-methyl-1-[(1-naphthalenyl)methyl]-1H-indole (796mg, 2.8 mmol) was treated with 112mg (2.8 mmol) of 60%  $\text{NaH}$ /mineral oil and then 0.27 mL (0.27 mmol) of methyl bromoacetate. The product was purified by chromatography over silica gel eluting with 20% EtOAc/hexane to give 450mg (45% yield) of [[2-methyl-1-[(1-naphthalenyl)methyl]-1H-indol-4-yl]oxy]acetic acid methyl ester, 167-171°C.

Analyses for  $\text{C}_{23}\text{H}_{21}\text{NO}_3$ :

Calculated:	C, 76.86;	H, 5.89;	N, 3.90
Found:	C, 77.95;	H, 6.25;	N, 3.72.

**Part D.** Preparation of [[3-(2-Amino-1,2-dioxoethyl)-2-methyl-1-[(1-naphthalenyl)methyl]-1H-indol-4-yl]oxy]acetic acid methyl ester.

Using the procedure in Example 1, Part F, 445g (1.24 mmol) of [[2-methyl-1-[(1-naphthalenyl)methyl]-1H-indol-4-yl]oxy]acetic acid methyl ester was reacted first with 0.11 mL (1.24 mmol) of oxalyl chloride and then excess ammonia to give a white solid. This was stirred with ethyl acetate and water. The EtOAc was washed with brine, dried ( $\text{MgSO}_4$ ) and concentrated at reduced pressure. The residue was chromatographed on silica gel eluting with ethyl acetate to give 409mg of [[3-(2-amino-1,2-dioxoethyl)-2-methyl-1-[(1-naphthalenyl)methyl]-1H-indol-4-yl]oxy]acetic acid methyl ester, mp 188-190°C.

Analyses for  $\text{C}_{25}\text{H}_{22}\text{N}_2\text{O}_5$ :

Calculated:	C, 69.76;	H, 5.15;	N, 6.51
Found:	C, 69.94;	H, 5.28;	N, 6.55.

**Part E.** Preparation of [[3-(2-Amino-1,2-dioxoethyl)-2-methyl-1-[(1-naphthalenyl)methyl]-1H-indol-4-yl]oxy]acetic acid.


A mixture of 402mg (0.93 mmol) of [[3-(2-amino-1,2-dioxoethyl)-2-methyl-1-[(1-naphthalenyl)methyl]-1H-indol-4-yl]oxy]acetic acid, 5 mL of 1N  $\text{NaOH}$  and 15 mL of  $\text{MeOH}$  was heated to maintain reflux for 0.5 hours, stirred at room temperature for 0.5 h and concentrated at reduced pressure. The residue was taken up in ethyl acetate and water, the aqueous layer separated and made acidic to pH 2-3 with 1N  $\text{HCl}$ . The mixture was extracted with ethyl acetate, the ethyl acetate was washed with brine, dried ( $\text{MgSO}_4$ ), and concentrated at reduced pressure. The residue was stirred with ether/methylene chloride and filtered to give 284mg (73% yield) of [[3-(2-amino-1,2-dioxoethyl)-2-methyl-1-[(1-naphthalenyl)methyl]-1H-indol-4-yl]oxy]acetic acid, mp, 233-235°C.

Analyses for  $\text{C}_{24}\text{H}_{20}\text{N}_2\text{O}_5$ :

Calculated:	C, 69.22;	H, 4.84;	N, 6.73
Found:	C, 68.98;	H, 5.01;	N, 6.36.

**Example 9**

Preparation of [[3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid, a compound represented by the formula:

**Part A. Preparation of 2-Ethyl-4-methoxy-1H-indole.**

A solution of 140 mL (0.18 mol) of 1.3M sec-butyl lithium in cyclohexane was added slowly to N-tert-butoxycarbonyl-3-methoxy-2-methylaniline (21.3g, 0.09 mol) in 250 mL of THF keeping the temperature below -40°C with a dry ice-ethanol bath. The bath was removed and the temperature allowed to rise to 0°C and then the bath replaced. After the temperature had cooled to -60°C, 18.5g (0.18 mol) of N-methoxy-N-methylpropanamide in an equal volume of THF was added dropwise. The reaction mixture was stirred 5 minutes, the cooling bath removed and stirred an additional 18 hours. It was then poured into a mixture of 300 mL of ether and 400 mL of 0.5N HCl. The organic layer was separated, washed with water, brine, dried over MgSO<sub>4</sub>, and concentrated at reduced pressure to give 25.5g of a crude of 1-[2-(tert-butoxycarbonylamino)-6-methoxyphenyl]-2-butanone. This material was dissolved in 250 mL of methylene chloride and 50 mL of trifluoroacetic acid and stirred for a total of 17 hours. The mixture was concentrated at reduced pressure and ethyl acetate and water added to the remaining oil. The ethyl acetate was separated, washed with brine, dried (MgSO<sub>4</sub>) and concentrated. The residue was chromatographed three times on silica eluting with 20% EtOAc/hexane to give 13.9g of 2-ethyl-4-methoxy-1H-indole.

**Analyses for C<sub>11</sub>H<sub>13</sub>NO:**

Calculated:	C, 75.40;	H, 7.48;	N, 7.99
Found:	C, 74.41;	H, 7.64;	N, 7.97.

**Part B. Preparation of 2-Ethyl-4-methoxy-1-(phenylmethyl)-1H-indole.**

2-Ethyl-4-methoxy-1H-indole (4.2g, 24 mmol) was dissolved in 30 mL of DMF and 960mg (24 mmol) of 60% NaH/mineral oil was added. After 1.5 hours, 2.9 mL (24 mmol) of benzyl bromide was added. After 4 hours, the mixture was diluted with water and extracted twice with ethyl acetate. The combined ethyl acetate was washed with brine, dried (MgSO<sub>4</sub>) and concentrated at reduced pressure. The residue was chromatographed on silica gel and eluted with 20% EtOAc/hexane to give 3.1g (49% yield) of 2-ethyl-4-methoxy-1-(phenylmethyl)-1H-indole.

**Part C. Preparation of 2-Ethyl-4-hydroxy-1-(phenylmethyl)-1H-indole.**

By the method used in Example 1, Part D, 3.1g (11.7 mmol) of 2-ethyl-4-methoxy-1-(phenylmethyl)-1H-indole was O-demethylated by treating it with 48.6 mL of 1M BBr<sub>3</sub>/CH<sub>2</sub>Cl<sub>2</sub> to give a material that was chromatographed on silica gel (eluted with 20% EtOAc/hexane) to give 1.58g (54% yield) of 2-ethyl-4-hydroxy-1-(phenylmethyl)-1H-indole, mp, 86-90°C.

Analyses for  $C_{17}H_{17}NO$ :

Calculated:	C, 81.24;	H, 6.82;	N, 5.57
Found:	C, 81.08;	H, 6.92;	N, 5.41.

Part D. Preparation of [[2-Ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester.

Using the procedure described in Example 1, Part E, 2-ethyl-4-hydroxy-1-(phenylmethyl)-1H-indole (1.56g, 6.2 mmol) was treated with 248mg (6.2 mmol) of 60% NaH/mineral oil and then 0.6 mL (6.2 mmol) of methyl bromoacetate. The product was purified by chromatography over silica gel eluting with 20% EtOAc/hexane, to give 1.37g (69% yield) of [[2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester, 89-92°C.

Analyses for  $C_{20}H_{21}NO_3$ :

Calculated:	C, 74.28;	H, 6.55;	N, 4.33
Found:	C, 74.03;	H, 6.49;	N, 4.60.

Part E. Preparation of [[3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester.

Using the procedure in Example 1, Part F, 1.36g (4.2 mmol) of [[2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester was reacted first with 0.4 mL (4.2 mmol) of oxalyl chloride and then excess ammonia to give a white solid. This was stirred with ethyl acetate and the insoluble material separated and dried to give 1.37g of a mixture of [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester and ammonium chloride. This mixture melted at 172-187°C.

Part F. Preparation of [[3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid.


A mixture of 788mg (2 mmol) of [3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester, 10 mL of 1N NaOH and 30 mL of MeOH was heated to maintain reflux for 0.5 hour, stirred at room temperature for 0.5 hour and concentrated at reduced pressure. The residue was taken up in ethyl acetate and water, the aqueous layer separated and made acidic to pH 2-3 with 1N HCl. The precipitate was filtered and washed with ethyl acetate to give 559mg (74% yield) of [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid, mp, 230-234°C.

Analyses for  $C_{21}H_{20}N_2O_5$ :

Calculated:	C, 65.96;	H, 5.80;	N, 7.33
Found:	C, 66.95;	H, 5.55;	N, 6.99.

Example 10

Preparation of [[3-(2-Amino-1,2-dioxoethyl)-1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]acetic acid, a compound represented by the formula:



**Part A. Preparation of 1-[(3-Chlorophenyl)methyl]-2-ethyl-4-methoxy-1H-indole.**

Using the procedure in Example 1, Part C, 1.61g (9.2 mmol) of 2-ethyl-4-methoxy-1H-indole was reacted with 368mg (9.2 mmol) of 60% NaH/mineral oil and then 1.2 mL (9.2 mmol) of 3-chlorobenzyl chloride in 10 mL of DMF to give a 1.34g (49% yield) of 1-[(3-chlorophenyl)methyl]-2-ethyl-4-methoxy-1H-indole after chromatography on silica gel (eluting with 20% EtOAc/hexane).

**Part B. Preparation of 1-[(3-Chlorophenyl)methyl]-2-ethyl-4-hydroxy-1H-indole.**

By the same procedure as in Example 1, Part D, 1.34g (4.5 mmol) of 1-[(3-chlorophenyl)methyl]-2-ethyl-4-hydroxy-1H-indole was O-demethylated using 36 mL of 1N BBr<sub>3</sub> to give after chromatography of silica gel (eluted with 5% MeOH/EtOAc 512mg (40% yield) of 1-[(3-chlorophenyl)methyl]-2-ethyl-4-hydroxy-1H-indole.

**Part C. Preparation of [[1-[(3-Chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]acetic acid methyl ester.**

Using the procedure described in Example 1, Part E, 1-[(3-chlorophenyl)methyl]-2-ethyl-4-hydroxy-1H-indole (512mg, 1.8 mmol) was treated with 72mg (1.8 mmol) of 60% NaH/mineral oil and then 0.17 mL (1.8 mmol) of methyl bromoacetate. The product was purified by chromatography over silica gel eluting with 20% EtOAc/hexane, to give 418mg (65% yield) of [[1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]acetic acid methyl ester, mp, 85-90°C.

**Analyses for C<sub>20</sub>H<sub>20</sub>ClNO<sub>3</sub>:**

Calculated:	C, 67.13;	H, 5.63;	N, 3.91
Found:	C, 64.41;	H, 5.63;	N, 3.10.

**Part D. [[3-(2-Amino-1,2-dioxoethyl)1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]acetic acid methyl ester.**

Using the procedure in Example 1, Part F, 410mg (1.15 mmol) of [[1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]acetic acid methyl ester was reacted first with 0.1 mL (1.15 mmol) of oxalyl chloride and then excess ammonia to give a white solid. This solid was stirred with ethyl acetate and the insoluble material separated and dried to give 424mg of a mixture of [[3-(2-amino-1,2-dioxoethyl)1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]acetic acid methyl ester and ammonium chloride. This mixture melted at 173-185°C.

**Part E. Preparation of [[3-(2-Amino-1,2-dioxoethyl)1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]acetic acid.**

Using the procedure described in Example 2, Part E, 418mg (1 mmol) of [[3-(2-amino-1,2-dioxoethyl)1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]acetic acid methyl ester was hydrolyzed in 5 mL of 1N NaOH and 15 mL of MeOH to give 268mg (61% yield) of [[3-(2-amino-1,2-dioxoethyl)1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]acetic acid, sodium salt, mp, >265°C.

Analyses for  $C_{21}H_{18}ClN_2O_5Na$ :

Calculated:	C, 57.74;	H, 4.15;	N, 6.41
Found:	C, 58.36;	H, 4.61;	N, 5.57.


There was also obtained 60mg (14% yield) of [[3-(2-amino-1,2-dioxoethyl)-1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]acetic acid, mp, 210-212°C.

Analyses for  $C_{21}H_{18}ClN_2O_5$ :

Calculated:	C, 60.88;	H, 4.61;	N, 6.75
Found:	C, 60.53;	H, 4.78;	N, 6.59.

**Example 11**

Preparation of [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-ethyl-1H-indol-4-yl]oxy]acetic acid, a compound represented by the formula:

**Part A.** Preparation of 1-([1,1'-biphenyl]-2-ylmethyl)-2-ethyl-4-methoxy-1H-indole.

Using the procedure described in Example 1, Part C, 1.75g (10 mmol) of 2-ethyl-4-methoxy-1H-indole was reacted with 400mg (10 mmol) of 60% NaH/mineral oil and then 1.83 mL (10 mmol) of 2-(bromomethyl)biphenyl to give after chromatography on silica (eluting with 20% EtOAc/hexane) 1.25g (37% yield) of 1-([1,1'-biphenyl]-2-ylmethyl)-2-ethyl-4-methoxy-1H-indole as an oil.

**Part B.** Preparation of 1-([1,1'-Biphenyl]-2-ylmethyl)-2-ethyl-4-hydroxy-1H-indole.

By the method used in Example 1, Part D, 911mg (2.6 mmol) of 1-([1,1'-biphenyl]-2-ylmethyl)-2-ethyl-4-methoxy-1H-indole was O-demethylated by treating it with 10 mL of 1M BBr<sub>3</sub>/CH<sub>2</sub>Cl<sub>2</sub>. The crude product was chromatographed on silica gel and eluted with 20% EtOAc/hexane to give 590mg (69% yield) of 1-([1,1'-biphenyl]-2-ylmethyl)-2-ethyl-4-hydroxy-1H-indole as an oil.

**Part C.** Preparation of [[1-([1,1'-Biphenyl]-2-ylmethyl)-2-ethyl-1H-indol-4-yl]oxy]acetic acid methyl ester.

1-([1,1'-Biphenyl]-2-ylmethyl)-2-ethyl-4-hydroxy-1H-indole (911mg, 2.8 mmol) was alkylated by treating with 0.26 mL (2.8 mmol) of methyl bromoacetate and 111mg (2.8 mmol) of 60% NaH/mineral oil in DMF as described in Example 1, Part E. The product was purified by chromatography over silica gel eluting with 20% EtOAc/hexane, to give 655mg (59% yield) of [[1-([1,1'-biphenyl]-2-ylmethyl)-2-ethyl-1H-indol-4-yl]oxy]acetic

acid methyl ester.

**Part D.** Preparation of [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-ethyl-1H-indol-4-yl]oxy]acetic acid methyl ester.

Oxalyl chloride (0.12 mL, 1.4 mmol) was added to 555mg (1.4 mmol) of [[1-([1,1'-biphenyl]-2-ylmethyl)-2-ethyl-1H-indol-4-yl]oxy]acetic acid methyl ester in 10 mL of methylene chloride and the mixture stirred for 2.5 hours at room temperature. The mixture was concentrated at reduced pressure, the residue redissolved in 10 mL of methylene chloride, anhydrous ammonia bubbled in for 0.25 hours and the precipitate filtered. This precipitate was chromatographed on silica gel and eluted with EtOAc to give 605mg (92% yield) of [[3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-ethyl-1H-indol-4-yl]oxy]acetic acid methyl ester.

**Part E.** Preparation of [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-ethyl-1H-indol-4-yl]oxy]acetic acid.


A mixture of 600mg (1.3 mmol) of [[3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-ethyl-1H-indol-4-yl]oxy]acetic acid methyl ester in 8 mL of 1N NaOH and 20 mL of MeOH was heated to maintain reflux for 0.67 hours, concentrated at reduced pressure and the residue taken up in EtOAc/water. The aqueous layer was separated, made acidic with 1N HCl and extracted with EtOAc. The EtOAc solution was dried (MgSO<sub>4</sub>) and evaporated and the residue crystallized from MeOH to give 352mg (59% yield) of [[3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-ethyl-1H-indol-4-yl]oxy]acetic acid, mp, 211-214°C.

Analyses for C<sub>27</sub>H<sub>24</sub>N<sub>2</sub>O<sub>6</sub>:

Calculated:	C, 71.04;	H, 5.30;	N, 6.14
Found:	C, 71.26;	H, 5.54;	N, 5.98.

### Example 12

Preparation of [[3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-propyl-1H-indol-4-yl]oxy]acetic acid, a compound represented by the formula:



### Part A. Preparation of 4-Methoxy-2-propyl-1H-indole.

A solution of 50 mL (65 mmol) of 1.3M sec-butyl lithium in cyclohexane was added slowly to N-tert-butoxycarbonyl-3-methoxy-2-methylaniline (7.7g, 32.5 mmol) in 100 mL of THF keeping the temperature below -40°C with a dry ice-ethanol bath. The bath was removed and the temperature allowed to rise to -10°C and then the bath replaced. After the temperature had cooled to -60°C, 4.3g (32.5 mmol) of N-methoxy-N-methylbutanamide in an equal volume of THF was added dropwise. The reaction mixture was stirred 1 hour, the cool-

ing bath removed and stirred an additional 22 hours. It was then poured into a mixture of 200 mL of ether and 200 mL of 0.5N HCl. The organic layer was separated, washed with brine, dried over  $\text{MgSO}_4$ , and concentrated at reduced pressure to give 9.9g of crude 1-[2-(tert-butoxycarbonylamino)-6-methoxyphenyl]-2-pentanone. This material was dissolved in 100 mL of methylene chloride and 20 mL of trifluoroacetic acid and stirred for a total of 23 hours. The mixture was washed with water, dried ( $\text{MgSO}_4$ ) and concentrated at reduced pressure. The residue was chromatographed on silica gel eluting with 20% EtOAc/hexane to give 2.19g of 4-methoxy-2-propyl-1H-indole as an oil.

Analyses for  $\text{C}_{12}\text{H}_{15}\text{NO}$ :

Calculated:	C, 76.16;	H, 7.99;	N, 7.40
Found:	C, 74.18;	H, 8.10;	N, 6.51.

Part B. Preparation of 1-([1,1'-biphenyl]-2-ylmethyl)-4-methoxy-2-propyl-1H-indole.

Using the procedure described in Example 1, Part C, 945mg (5 mmol) of 4-methoxy-2-propyl-1H-indole was reacted with 200mg (5 mmol) of 60% NaH/mineral oil and then 0.92 mL (5 mmol) of 2-(bromomethyl)biphenyl to give after chromatography on silica gel (eluting with 20% EtOAc/hexane) 1.16g (65% yield) of 1-([1,1'-biphenyl]-2-ylmethyl)-4-methoxy-2-propyl-1H-indole as an oil.

Part C. Preparation of 1-([1,1'-Biphenyl]-2-ylmethyl)-4-hydroxy-2-propyl-1H-indole.

By the method used in Example 1, Part D, 1.16g (3.27 mmol) of 1-([1,1'-biphenyl]-2-ylmethyl)-4-methoxy-2-propyl-1H-indole was O-demethylated by treating it with 13 mL of 1M  $\text{BBr}_3/\text{CH}_2\text{Cl}_2$ . The crude product was chromatographed on silica gel and eluted with 20% EtOAc/hexane to give 794mg (71% yield) of 1-([1,1'-biphenyl]-2-ylmethyl)-4-hydroxy-2-propyl-1H-indole as an oil.

Part D. Preparation of [[1-([1,1'-Biphenyl]-2-ylmethyl)-2-propyl-1H-indol-4-yl]oxy]acetic acid methyl ester.

1-([1,1'-Biphenyl]-2-ylmethyl)-4-hydroxy-2-propyl-1H-indole (794mg, 2.8 mmol) was alkylated by treating with 0.22 mL (2.3 mmol) of methyl bromoacetate and 93mg (2.3 mmol) of 60% NaH/mineral oil in DMF as described in Example 1, Part E. The product was purified by chromatography over silica gel eluting with 20% EtOAc/hexane, to give 533mg (56% yield) of [[1-([1,1'-biphenyl]-2-ylmethyl)-2-propyl-1H-indol-4-yl]oxy]acetic acid methyl ester.

Part E. Preparation of [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-propyl-1H-indol-4-yl]oxy]acetic acid methyl ester.

Oxalyl chloride (0.11 mL, 1.3 mmol) was added to 533mg (1.3 mmol) of [[1-([1,1'-biphenyl]-2-ylmethyl)-2-propyl-1H-indol-4-yl]oxy]acetic acid methyl ester in 10 mL of methylene chloride and the mixture stirred for 2.0 hours at room temperature. The mixture was concentrated at reduced pressure, the residue redissolved in 10 mL of methylene chloride, anhydrous ammonia bubbled in for 0.25 hours and the mixture concentrated at reduced pressure. The residue was taken up in EtOAc/water, the EtOAc separated, washed with brine and dried ( $\text{MgSO}_4$ ). After concentrating, the residue was chromatographed on silica and eluted with EtOAc to give 440mg (70% yield) of [[3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-propyl-1H-indol-4-yl]oxy]acetic acid methyl ester.

Part F. Preparation of [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-propyl-1H-indol-4-yl]oxy]acetic acid.

A mixture of 440mg (0.9 mmol) of [[3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-propyl-1H-indol-4-yl]oxy]acetic acid methyl ester in 5 mL of 1N NaOH and 15 mL of MeOH was stirred for 0.75 hours, concentrated at reduced pressure and the residue taken up in EtOAc/water. The aqueous layer was separated, made acidic with 1N HCl to pH 2-3 and extracted with EtOAc. The EtOAc solution was dried ( $\text{MgSO}_4$ ) and evaporated to give 374mg (88% yield) of [[3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-propyl-1H-indol-4-yl]oxy]acetic acid.


Analyses for  $\text{C}_{28}\text{H}_{28}\text{N}_2\text{O}_5$ :

Calculated:	C, 71.47;	H, 5.57;	N, 5.95
Found:	C, 69.58;	H, 5.65;	N, 5.53.

Example 13

Preparation of [[3-(2-Amino-1,2-dioxoethyl)-2-cyclopropyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic

acid, a compound represented by the formula:



**Part A. Preparation of 2-Cyclopropyl-4-methoxy-1H-indole.**

Using the procedure described in Example 9, Part A, 100 mL (130 mmol) of 1.3M sec-butyl lithium in cyclohexane was reacted with N-tert-butoxycarbonyl-3-methoxy-2-methylaniline (15.4g, 65 mmol) in 100 mL of THF and then with 8.4g (65 mmol) of N-methoxy-N-methylcyclopropylcarboxamide to give crude [2-(tert-butoxycarbonylamino)-6-methoxyphenyl]methyl cyclopropyl ketone. This material on treatment with 20 mL of trifluoroacetic acid in 300 mL of methylene chloride for 6 hours gave a material that was chromatographed on silica gel. Eluting with a gradient, toluene→5% EtOAc/toluene, there was obtained 6.4g (52% yield) of 2-cyclopropyl-4-methoxy-1H-indole as an oil.

**Analyses for C<sub>12</sub>H<sub>13</sub>NO:**

Calculated:	C, 76.98;	H, 7.00;	N, 7.48
Found:	C, 74.33;	H, 7.11;	N, 6.62.

**Part B. Preparation of 2-Cyclopropyl-4-methoxy-1-(phenylmethyl)-1H-indole.**

Using the procedure described in Example 1, Part C, 935mg (5 mmol) of 2-cyclopropyl-4-methoxy-1H-indole was reacted with 200mg (5 mmol) of 60% NaH/mineral oil and then 0.6 mL (5 mmol) of benzyl bromide to give after chromatography on silica gel (eluting with 20% EtOAc/hexane) 630mg (45% yield) of 2-cyclopropyl-4-methoxy-1-(phenylmethyl)-1H-indole as an oil.

**Part C. Preparation of 2-Cyclopropyl-4-hydroxy-1-(phenylmethyl)-1H-indole.**

By the method used in Example 1, Part D, 630g (2.3 mmol) of 2-cyclopropyl-4-methoxy-1-(phenylmethyl)-1H-indole was O-demethylated by treating it with 9 mL of 1M BBr<sub>3</sub>/CH<sub>2</sub>Cl<sub>2</sub>. The crude product was chromatographed on silica gel and eluted with 20% EtOAc/hexane to give 316mg (52% yield) of 2-cyclopropyl-4-hydroxy-1-(phenylmethyl)-1H-indole as an oil.

**Part D. Preparation of [[2-Cyclopropyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester.**

2-Cyclopropyl-4-hydroxy-1-(phenylmethyl)-1H-indole (316mg, 1.2 mmol) was alkylated by treating with 0.11 mL (1.2 mmol) of methyl bromoacetate and 48mg (1.2 mmol) of 60% NaH/mineral oil in DMF as described in Example 1, Part E. The product was purified by chromatography over silica gel eluting with 20% EtOAc/hexane, to give 253mg (63% yield) of [[2-cyclopropyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester.

**Part E. Preparation of [[3-(2-Amino-1,2-dioxoethyl)-2-cyclopropyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester.**

Oxalyl chloride (0.07 mL, 0.76 mmol) was added to 253mg (0.76 mmol) of [[2-cyclopropyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester in 10 mL of methylene chloride and the mixture stirred for 1.5 hours at room temperature. The mixture was concentrated at reduced pressure, the residue redissolved in 10 mL of methylene chloride, anhydrous ammonia bubbled in for 0.25 hours. A precipitate formed and was separated to give 226mg of a mixture of [[3-(2-amino-1,2-dioxoethyl)-2-cyclopropyl-1-(phenylmethyl)-1H-indol-4-



yl]oxy]acetic acid methyl ester and ammonium chloride.

**Part F.** Preparation of [[3-(2-Amino-1,2-dioxoethyl)-2-cyclopropyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid


A mixture of 220mg (0.54 mmol) of [[3-(2-amino-1,2-dioxoethyl)-2-cyclopropyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid methyl ester in 5 mL of 1N NaOH and 15 mL of MeOH was heated to maintain reflux for 0.67 hours, concentrated at reduced pressure and the residue taken up in EtOAc/water. The aqueous layer was separated, made acidic with 1N HCl to pH 2-3 and EtOAc added. A precipitate formed and was separated to give 169mg (80% yield) of [[3-(2-amino-1,2-dioxoethyl)-2-cyclopropyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid, mp, 246-249°C.

Analyses for  $C_{22}H_{20}N_2O_6$ :

Calculated:	C, 67.34;	H, 5.14;	N, 7.14
Found:	C, 67.11;	H, 5.33;	N, 6.86.

**Example 14**

Preparation of [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-cyclopropyl-1H-indol-4-yl]oxy]acetic acid, a compound represented by the formula:



**Part A.** Preparation of 1-([1,1'-Biphenyl]-2-ylmethyl)-2-cyclopropyl-4-methoxy-1H-indole.

Using the procedure described in Example 1, Part C, 935mg (5 mmol) of 2-cyclopropyl-4-methoxy-1H-indole was reacted with 200mg (5 mmol) of 60% NaH/mineral oil and then 0.92 mL (5 mmol) of 2-(bromomethyl)biphenyl to give after chromatography on silica gel (eluting with 20% EtOAc/hexane) 911mg (52% yield) of 1-([1,1'-biphenyl]-2-ylmethyl)-2-cyclopropyl-4-methoxy-1H-indole as an oil.

**Part B.** Preparation of 1-([1,1'-Biphenyl]-2-ylmethyl)-2-cyclopropyl-4-hydroxy-1H-indole.

By the method used in Example 1, Part D, 1.25g (3.7 mmol) of 1-([1,1'-biphenyl]-2-ylmethyl)-2-cyclopropyl-4-methoxy-1H-indole was O-demethylated by treating it with 15 mL of 1M  $BBr_3/CH_2Cl_2$ . The crude product was chromatographed on silica gel and eluted with 20% EtOAc/hexane to give 367mg (29% yield) of 1-([1,1'-biphenyl]-2-ylmethyl)-2-cyclopropyl-4-hydroxy-1H-indole as an oil.

**Part C.** Preparation of [[1-([1,1'-Biphenyl]-2-ylmethyl)-2-cyclopropyl-1H-indol-4-yl]oxy]acetic acid methyl ester.

1-([1,1'-Biphenyl]-2-ylmethyl)-2-cyclopropyl-4-hydroxy-1H-indole (367mg, 1.1 mmol) was alkylated by treating with 0.1 mL (1.1 mmol) of methyl bromoacetate and 43mg (1.1 mmol) of 60% NaH/mineral oil in DMF

as described in Example 1, Part E. The product was purified by chromatography over silica gel eluting with 20% EtOAc/hexane to give 265mg (59% yield) of [[1-([1,1'-biphenyl]-2-ylmethyl)-2-cyclopropyl-1H-indol-4-yl]oxy]acetic acid methyl ester.

**Part D.** Preparation of [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-cyclopropyl-1H-indol-4-yl]oxy]acetic acid methyl ester.

Oxalyl chloride (0.06 mL, 0.64 mmol) was added to 265mg (0.64 mmol) of [[1-([1,1'-biphenyl]-2-ylmethyl)-2-cyclopropyl-1H-indol-4-yl]oxy]acetic acid methyl ester in 10 mL of methylene chloride and the mixture stirred for 1.5 hours at room temperature. The mixture was concentrated at reduced pressure, the residue redissolved in 10 mL of methylene chloride, anhydrous ammonia bubbled in for 0.25 hours and the mixture concentrated at reduced pressure. The residue was taken up in EtOAc/water, the EtOAc separated, washed with brine and dried (MgSO<sub>4</sub>). After concentrating, the residue was chromatographed on silica and eluted with EtOAc to give 181mg (59% yield) of [[3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-cyclopropyl-1H-indol-4-yl]oxy]acetic acid methyl ester.

**Part E.** Preparation of [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-cyclopropyl-1H-indol-4-yl]oxy]acetic acid.


A mixture of 175mg (0.36 mmol) of [[3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-cyclopropyl-1H-indol-4-yl]oxy]acetic acid methyl ester in 4 mL of 1N NaOH and 10 mL of MeOH was stirred for 0.5 hours, concentrated at reduced pressure and the residue taken up in EtOAc/water. The aqueous layer was separated, made acidic with 1N HCl to pH 2-3 and extracted with EtOAc. The EtOAc solution was dried (MgSO<sub>4</sub>), evaporated and the residue stirred with EtOAc/ether. The insoluble material was filtered to give 105mg (62% yield) of [[3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-cyclopropyl-1H-indol-4-yl]oxy]acetic acid, mp, 172-174°C.

Analyses for C<sub>28</sub>H<sub>24</sub>N<sub>2</sub>O<sub>5</sub>:

Calculated:	C, 71.78;	H, 5.16;	N, 5.98
Found:	C, 72.08;	H, 5.30;	N, 5.92.

### Example 15

Preparation of 4-[[3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-5-yl]oxy]butanoic acid, a compound represented by the formula:



**Part A.** Preparation of N-tert-Butoxycarbonyl-4-methoxy-2-methylaniline.

By the procedure in Example 1, Part A, 13.7 g (0.1 mole) of 4-methoxy-2-methylaniline was reacted with 25g (0.1145 mol) of di-tert-butyl dicarbonate to give 17.25 g (73% yield) of N-tert-butoxycarbonyl-4-methoxy-2-methylaniline melting at 80-82°C, after crystallizing from hexane.

Analyses for  $C_{13}H_{19}NO_3$ :

Calculated:	C, 65.80;	H, 8.07;	N, 5.90
Found:	C, 65.86;	H, 8.15;	N, 5.61.

**Part B.** Preparation of 1-[2-(*tert*-Butoxycarbonylamino)-5-methoxyphenyl]-2-butanone.

A solution of 1.3M *sec*-butyl lithium/cyclohexane (81 mL, 0.105 mol) was added slowly to 11.85g (0.05 mol) of *N*-*tert*-butoxycarbonyl-4-methoxy-2-methylaniline in 80 mL of THF while keeping the temperature below -40°C with a dry ice-ethanol bath. The bath was removed and the temperature allowed to rise to -20°C and then the bath was replaced. After the temperature had cooled to -60°C, 6.1g (0.052 mol) of *N*-methoxy-*N*-methylpropanamide in an equal volume of THF was added dropwise. The reaction mixture was stirred 1 hour, the cooling bath removed and stirred an additional 1 hour. It was then poured into a mixture of 200 mL of ether and 200 mL of 1N HCl. The organic layer was separated, washed with water, dried over  $Na_2SO_4$  and concentrated at reduced pressure to give 10.9g (74% yield) of 1-(2-(*tert*-butoxycarbonylamino)-5-methoxyphenyl)-2-butanone, melting at 80-81°C, after chromatography on silica eluting with 5% EtOAc/toluene.

Analyses for  $C_{16}H_{23}NO_4$ :

Calculated:	C, 65.51;	H, 7.90;	N, 4.77
Found:	C, 65.69;	H, 7.89;	N, 4.90.

**Part C.** Preparation of 2-Ethyl-5-methoxy-1H-indole.

1-[2-(*tert*-Butoxycarbonylamino)-5-methoxyphenyl]-2-butanone (7.33 g, 0.025 mol) in 120 mL of  $CH_2Cl_2$  and 20 mL of trifluoroacetic acid was stirred for 20 hours, washed with water,  $NaHCO_3$  solution and the product chromatographed on silica (eluted with 20% EtOAc/hexane) to give 2.54g (58% yield) of 2-ethyl-5-methoxy-1H-indole as a white solid, mp 49-50°C.

Analyses for  $C_{11}H_{13}NO$ :

Calculated: C, 75.40; H, 7.48; N, 7.99

Found: C, 75.64; H, 7.61; N, 8.04.

**Part D.** Preparation of 2-Ethyl-5-methoxy-1-(phenylmethyl)-1H-indole.

2-Ethyl-5-methoxy-1H-indole (5.6g, 21.5 mmol) was dissolved in 150 mL of DMF and 20 mL of THF and 1.0g (25 mmol) of 60% sodium hydride was added. After stirring for 0.17 hours, 3.0 mL (25 mmol) of benzyl bromide was added. The mixture was stirred at room temperature for 10 hours, diluted with water and extracted with ethyl acetate. The ethyl acetate solution was washed with water, saturated NaCl solution, and dried ( $Na_2SO_4$ ). The EtOAc was evaporated and the residue was chromatographed on silica gel eluting with a gradient, 5% EtOAc/hexane→15% EtOAc/hexane to give 4.6g (82% yield) of 2-ethyl-5-methoxy-1-(phenylmethyl)-1H-indole.

**Part E.** Preparation of 2-Ethyl-5-methoxy-2-methyl-1-(phenylmethyl)-1H-indole-3-glyoxylamide.

Oxalyl chloride (0.8 mL, 9.2 mmol) was added to 2.1g (7.9 mmol) of 2-ethyl-5-methoxy-1-(phenylmethyl)-1H-indole while being cooled to -5°C. The cooling bath was removed, stirring was continued for 1 hour and the mixture added at 0-5°C to 150 mL of THF saturated with ammonia. After 0.33 hours, the mixture was diluted with water, the organic layer separated, washed with saturated NaCl solution and dried ( $Na_2SO_4$ ). After concentrating at reduced pressure, the residue was chromatographed on silica gel eluting first with methylene chloride and then ether to give 2.1g (79% yield) of 2-ethyl-5-methoxy-2-methyl-1-(phenylmethyl)-1H-indole-3-glyoxylamide.

**Part F.** Preparation of 2-Ethyl-5-hydroxy-2-methyl-1-(phenylmethyl)-1H-indole-3-glyoxylamide.

A solution of 1.3g (4 mmol) of 2-ethyl-5-methoxy-2-methyl-1-(phenylmethyl)-1H-indole-3-glyoxylamide and 16 mL of 1M  $BBr_3/CH_2Cl_2$  in 50 mL of methylene chloride was stirred for 1.5 hours, stirred with water, the organic material separated and washed with brine. After drying, the solution was concentrated at reduced pres-

sure and the residue chromatographed on silica gel. The material was eluted with a gradient, 1% MeOH/CH<sub>2</sub>Cl<sub>2</sub>→3% MeOH/CH<sub>2</sub>Cl<sub>2</sub>, to give after recrystallizing from methylene chloride-ethanol 270mg (21% yield) of 2-ethyl-5-hydroxy-2-methyl-1-(phenylmethyl)-1H-indole-3-glyoxylamide, mp 224-225°C.

Analyses for C<sub>19</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub>:

Calculated:	C, 70.70;	H, 5.63;	N, 8.69
Found:	C, 70.99;	H, 5.56;	N, 8.43.

**Part G.** Preparation of 4-[[3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-5-yl]oxy]butanoic acid tert-butyl ester.

2-Ethyl-5-hydroxy-2-methyl-1-(phenylmethyl)-1H-indole-3-glyoxylamide (355mg, 1.1 mmol) was dissolved in 10mL of THF and 20 mL of DMF and 50mg (1.2 mmol) of 60% NaH/mineral oil was added. After stirring for 0.17 hours, 290mg (1.3 mmol) of tert-butyl 4-bromobutyrate was added and stirring maintained for 4.75 hours. The mixture was diluted with water, extracted with EtOAc and the EtOAc washed with water, saturated NaCl solution and dried (Na<sub>2</sub>SO<sub>4</sub>). After concentrating at reduced pressure, the residue was chromatographed on silica gel and eluted with a gradient, CH<sub>2</sub>Cl<sub>2</sub>→2% MeOH/CH<sub>2</sub>Cl<sub>2</sub> to give after crystallizing from ether-hexane 460mg (90% yield) of 4-[[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-5-yl]oxy]butanoic acid tert-butyl ester, mp 101-104°C.

Analyses for C<sub>27</sub>H<sub>32</sub>N<sub>2</sub>O<sub>6</sub>:

Calculated:	C, 69.81;	H, 6.94;	N, 6.03
Found:	C, 70.54;	H, 7.02;	N, 6.37.

**Part H.** Preparation of 4-[[3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-5-yl]oxy]butanoic acid.


A solution of 450mg (0.97 mmol) of 4-[[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-5-yl]oxy]butanoic acid tert-butyl ester in 75 mL of methylene chloride and 1 mL of trifluoroacetic acid was stirred at room temperature for 2.25 hours and concentrated at reduced pressure. The residue was chromatographed on silica gel and eluted with EtOAc to give 250mg (63% yield) of 4-[[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-5-yl]oxy]butanoic acid, mp 173-175°C.

Analyses for C<sub>23</sub>H<sub>24</sub>N<sub>2</sub>O<sub>5</sub>:

Calculated:	C, 67.63;	H, 5.92;	N, 6.86
Found:	C, 67.09;	H, 6.00;	N, 6.76.

**Example 16**

Preparation of 4-[[3-(2-Amino-1,2-dioxoethyl)-1-(phenylmethyl)-1H-indol-5-yl]oxy]butanoic acid, a compound represented by the formula:



**Part A. 5-Hydroxy-1-(phenylmethyl)-1H-indole.**

5-Methoxy-1H-indole (5.6g, 21.5 mmol) was reacted with 1.0g (25 mmol) of 60% sodium hydride and then 3.0 mL (25 mmol) of benzyl bromide by the method described in Example 12, Part D to give crude 5-methoxy-1-(phenylmethyl)-1H-indole. This material was dissolved in 250 mL of methylene chloride, cooled to  $-5^{\circ}\text{C}$ , 50 mL of 1M  $\text{BBr}_3/\text{CH}_2\text{Cl}_2$  added, the cooling bath removed and the mixture stirred for 1.75 hours. Ice water was added and the mixture stirred. The organic layer was separated, washed with saturated NaCl, dried ( $\text{Na}_2\text{SO}_4$ ), and concentrated at reduced pressure. The residue was chromatographed on silica gel and eluted with 20% ether/hexane  $\rightarrow$  ether to give 870mg (19% overall yield) of crude 5-hydroxy-1-(phenylmethyl)-1H-indole.

**Part B. Preparation of 4-[[1-(Phenylmethyl)-1H-indol-5-yl]oxy]butanoic acid ethyl ester.**

A solution of 850mg (4.0 mmol) of 5-hydroxy-1-(phenylmethyl)-1H-indole in 75 mL of DMF and 20 mL of THF was treated with 200mg (5.0 mmol) of 60% NaH/mineral oil and after stirring for 0.17 hours, 0.7 mL (4.9 mmol) of ethyl 4-bromobutyrate was added. After 2.75 hours, the mixture was diluted with water and extracted with EtOAc. The EtOAc solution was washed with water, saturated NaCl solution, dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated at reduced pressure. The residue was chromatographed on silica gel and the 545mg (40% yield) of 4-[[1-(phenylmethyl)-1H-indol-5-yl]oxy]butanoic acid ethyl ester by eluting with a gradient, 15% ether/hexane  $\rightarrow$  50% ether/hexane.

**Part C. Preparation of 4-[[3-(2-Amino-1,2-dioxoethyl)-1-(phenylmethyl)-1H-indol-5-yl]oxy]butanoic acid ethyl ester.**

Oxalyl chloride (0.15 mL, 1.7 mmol) was added to 545mg (1.6 mmol) of 4-[[1-(phenylmethyl)-1H-indol-5-yl]oxy]butanoic acid ethyl ester in 40 mL of methylene chloride while cooling at  $-5^{\circ}\text{C}$ . The cooling bath was removed, the mixture stirred for 0.83 hours and added to 75 mL of THF saturated with ammonia gas at  $0-5^{\circ}\text{C}$ . After 0.25 hours, the mixture was diluted with water and extracted with methylene chloride. This solution was washed with saturated NaCl, dried ( $\text{Na}_2\text{SO}_4$ ), and concentrated at reduced pressure. The residue was crystallized from methylene chloride-ethanol to give 490mg (75% yield) of 4-[[3-(2-amino-1,2-dioxoethyl)-1-(phenylmethyl)-1H-indol-5-yl]oxy]butanoic acid ethyl ester, mp,  $168-170^{\circ}\text{C}$ .

**Analyses for  $\text{C}_{23}\text{H}_{24}\text{N}_2\text{O}_6$ :**

Calculated:	C, 67.63;	H, 5.92;	N, 6.86
Found:	C, 67.60;	H, 6.13;	N, 6.93.


**Part D. Preparation of 4-[[3-(2-Amino-1,2-dioxoethyl)-1-(phenylmethyl)-1H-indol-5-yl]oxy]butanoic acid.**

A mixture of 450mg (1.1 mmol) of 4-[[3-(2-amino-1,2-dioxoethyl)-1-(phenylmethyl)-1H-indol-5-yl]oxy]butanoic acid ethyl ester in 450 mL of THF and 50 mL of 5N HCl was stirred for 16 hours, diluted with EtOAc and washed with water, saturated NaCl solution and dried ( $\text{Na}_2\text{SO}_4$ ). After concentrating at reduced pressure, the residue was chromatographed on silica gel eluting first with 2% MeOH/ $\text{CH}_2\text{Cl}_2$  and then EtOAc to give after crystallization from MeOH- $\text{CH}_2\text{Cl}_2$  190mg (45% yield) of 4-[[3-(2-amino-1,2-dioxoethyl)-1-(phenylmethyl)-1H-indol-5-yl]oxy]butanoic acid, mp,  $193-195^{\circ}\text{C}$ .

Analyses for $C_{21}H_{20}N_2O_5$ :				
Calculated:	C, 66.31;	H, 5.30;	N, 7.36	
Found:	C, 60.82;	H, 5.08;	N, 6.64;	residue, 1.39%.

**Example 17**

Preparation of [[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]amino]acetic acid, a compound represented by the formula;

**Part A. Preparation of 1-Phenylmethyl-2-ethyl-4-nitro-1H-indole.**

2-Ethyl-4-nitro-1H-indole (4.75g, 25 mmol) was added to a mixture of 1.0g (25 mmol) of 60% NaH/mineral oil (washed with hexane before adding DMF) in 40ml DMF. After 45 minutes, 3.0ml (25 mmol) of benzyl bromide was added. The mixture was stirred at room temperature for four hours, diluted with water, and extracted with EtOAc. The EtOAc solution was washed with brine, dried over  $MgSO_4$ , and evaporated in vacuo. The residue was chromatographed on silica gel eluting with 20% EtOAc/Hexane to give 6.36g (91%) of 1-Phenylmethyl-2-ethyl-4-nitro-1H-indole as an oil.

Analyses for $C_{17}H_{16}N_2O_2$ :			
Calculated:	C, 72.84 ;	H, 5.75 ;	N, 9.99
Found:	C, 72.67 ;	H, 5.86 ;	N, 9.69

**Part B. Preparation of 2-Ethyl-4-Nitro- $\alpha$ -oxo-1-(phenylmethyl)-1H-indole-3-acetamide.**

Oxalyl chloride (1.98ml, 22.7 mmol) was added to 6.36g (22.7 mmol) of 1-Phenylmethyl-2-ethyl-4-nitro-1H-indole in 30ml of  $CH_2Cl_2$  and the mixture stirred for 7.5 hours. Another 0.5ml (5.7 mmol) of oxalyl chloride was then added and stirred an additional 16.5 hours. The mixture was concentrated at reduced pressure, the residue redissolved in 30ml  $CH_2Cl_2$ , and  $NH_3$  gas bubbled in for 0.25 hours. The mixture was evaporated in vacuo and the residue stirred with EtOAc and  $H_2O$ . The EtOAc layer was washed with brine, dried over  $MgSO_4$ , and evaporated in vacuo. The residue was chromatographed over silica gel eluting with 20%EtOAc/Hexane to give 6.0g (75%) of 2-Ethyl-4-Nitro- $\alpha$ -oxo-1-(phenylmethyl)-1H-indole-3-acetamide melting at 207-208°C.

Analyses for $C_{19}H_{17}N_3O_4$ :			
Calculated:	C, 64.95 ;	H, 4.88 ;	N, 11.96
Found:	C, 65.14 ;	H, 4.98 ;	N, 12.11

**Part C. Preparation of 4-Amino-2-Ethyl- $\alpha$ -oxo-1-(phenylmethyl)-1H-indole-3-Acetamide.**

A solution of 6.0g (17.1 mmol) of 2-Ethyl-4-Nitro- $\alpha$ -oxo-1-(phenylmethyl)-1H-indole-3-acetamide in 140ml of 1:1 THF:EtOH containing 1.0g of 5% Pt/ $BaSO_4$  was hydrogenated at room temperature and 60psi (4.22 Kg/cm<sup>2</sup>) for four hours. The catalyst was filtered and the filtrate evaporated in vacuo. The residue was chro-

matographed over silica gel eluting with Hexane/50 to 100% EtOAc to give 1.66g (30%) of 4-Amino-2-Ethyl- $\alpha$ -oxo-1-(phenylmethyl)-1H-indole-3-Acetamide melting at 140-144°C.

Analyses for $C_{19}H_{19}N_3O_2$ :			
Calculated:	C, 71.01 ;	H, 5.96 ;	N, 13.08
Found:	C, 68.50 ;	H, 5.93 ;	N, 11.88

**Part D.** Preparation of [[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]amino]acetic acid methyl ester.

Methyl bromoacetate (0.07ml, 0.78 mmol) was added to 250mg (0.78 mmol) of 4-Amino-2-Ethyl- $\alpha$ -oxo-1-(phenylmethyl) 1H-indole-3-Acetamide in 4ml of DMF, stirred at 60°C for 0.5 hour, and then at room temperature for 20 hours. The mixture was diluted with water and extracted with EtOAc. The EtOAc solution was washed with brine, dried over  $MgSO_4$ , and evaporated in vacuo. The residue was chromatographed over silica gel eluting with Hexane/50 to 100% EtOAc to give 196mg (64%) of [[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]amino]acetic acid methyl ester melting at 188-193°C.

Analyses for $C_{22}H_{23}N_3O_4$ :			
Calculated:	C, 67.16 ;	H, 5.89 ;	N, 10.68
Found:	C, 67.66 ;	N, 5.71 ;	N, 9.78

**Part E.** Preparation of [[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]amino]acetic acid.

A mixture of 190mg (0.48 mmol) of [[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]amino]acetic acid methyl ester, 5ml of 1N NaOH, and 15ml of MeOH was refluxed 0.33 hour, cooled, and stirred at room temperature for 1 hour. EtOAc and aqueous HCl were added and the EtOAc layer was washed with brine, dried over  $MgSO_4$ , and evaporated in vacuo. The residue was crystallized from MeOH to give 96mg (53%) of [[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]amino]acetic acid melting at 151-157°C.

Analyses for $C_{21}H_{21}N_3O_4$ :			
Calculated:	C, 66.48 ;	H, 5.58 ;	N, 11.08
Found:	C, 66.30 ;	H, 5.61 ;	N, 10.80

#### Assay Example 1

The following chromogenic assay procedure was used to identify and evaluate inhibitors of recombinant human secreted phospholipase  $A_2$ . The assay described herein has been adapted for high volume screening using 96 well microtiter plates. A general description of this assay method is found in the article, "Analysis of Human Synovial Fluid Phospholipase  $A_2$  on Short Chain Phosphatidylcholine-Mixed Micelles: Development of a Spectrophotometric Assay Suitable for a Microtiterplate Reader", by Laure J. Reynolds, Lori L. Hughes, and Edward A Dennis, *Analytical Biochemistry*, 204, pp. 190-197, 1992 (the disclosure of which is incorporated herein by reference):

Reagents:

##### REACTION BUFFER -

$CaCl_2 \cdot 2H_2O$  (1.47 g/L)

KCl (7.455 g/L)

Bovine Serum Albumin (fatty acid free) (1 g/L) (Sigma A-7030, product of Sigma Chemical Co. St. Louis MO, USA)

TRIS HCl (3.94 g/L)

pH 7.5 (adjust with NaOH)

##### ENZYME BUFFER -

0.05 NaOAc.3H<sub>2</sub>O, pH 4.5

0.2 NaCl

Adjust pH to 4.5 with acetic acid  
 DTNB - 5,5'-dithiobis-2-nitrobenzoic acid  
 RACEMIC DIHEPTANOYL THIO - PC  
 racemic 1,2-bis(heptanoylthio)-1,2-dideoxy-*sn*-glycero-3-phosphorylcholine  
 TRITON X-100™ prepare at 6.249 mg/ml in reaction buffer to equal 10uM.

#### REACTION MIXTURE -

A measured volume of racemic dipheptanoyl thio PC supplied in chloroform at a concentration of 100 mg/ml is taken to dryness and redissolved in 10 millimolar TRITON X-100™ nonionic detergent aqueous solution. Reaction Buffer is added to the solution, then DTNB to give the Reaction Mixture.

The reaction mixture thus obtained contains 1mM diheptanoyl thio-PC substrate, 0.29 mM Triton X-100™ detergent, and 0.12 mM DTMB in a buffered aqueous solution at pH 7.5.

#### Assay Procedure:

1. Add 0.2 ml reaction mixture to all wells;
2. Add 10 ul test compound (or solvent blank) to appropriate wells, mix 20 seconds;
3. Add 50 nanograms of sPLA<sub>2</sub> (10 microliters) to appropriate wells;
4. Incubate plate at 40°C for 30 minutes;
5. Read absorbance of wells at 405 nanometers with an automatic plate reader.

All compounds were tested in triplicate. Typically, compounds were tested at a final concentration of 5 ug/ml. Compounds were considered active when they exhibited 40% inhibition or greater compared to uninhibited control reactions when measured at 405 nanometers. Lack of color development at 405 nanometers evidenced inhibition. Compounds initially found to be active were reassayed to confirm their activity and, if sufficiently active, IC<sub>50</sub> values were determined. Typically, the IC<sub>50</sub> values (see, Table I, below) were determined by diluting test compound serially two-fold such that the final concentration in the reaction ranged from 45 ug/mL to 0.35 ug/ml. More potent inhibitors required significantly greater dilution. In all cases, % inhibition measured at 405 nanometers generated by enzyme reactions containing inhibitors relative to the uninhibited control reactions was determined. Each sample was titrated in triplicate and result values were averaged for plotting and calculation of IC<sub>50</sub> values. IC<sub>50</sub> were determined by plotting log concentration versus inhibition values in the range from 10-90% inhibition.

Results of Human Secreted Phospholipase A<sub>2</sub> Inhibition Tests for 1H-indole-3-glyoxylamides



Table I

Compound of Example No.	Inhibition of human secreted PLA <sub>2</sub> IC50 $\pm$ mean deviation	
	(3-4 tests)	
1	10.67 $\pm$ 5.51 nM	
2	9.00 $\pm$ 1.73 nM	
3	5.33 $\pm$ 1.15 nM	
4	9.69 $\pm$ 1.14 nM	
5	49.00 $\pm$ 11.53 nM	
6	6.00 $\pm$ 1.00 nM	
7	6.00 $\pm$ 1.00 nM	
8	32.75 $\pm$ 7.04 nM	
9	9.00 $\pm$ 1.73 nM	
10	6.67 $\pm$ 2.89 nM	
11	4.33 $\pm$ 2.31 nM	
12	82.23 $\pm$ 18.01 nM	
13	27.60 $\pm$ 13.07 nM	
14	5.57 $\pm$ 2.89 nM	
15	210 $\pm$ 60 nM	
16	62,010 $\pm$ 3750 nM	
17	1148 $\pm$ 120 nM	

The compounds of Examples 1 to 15 are highly active in inhibiting sPLA<sub>2</sub>. The compound of Example 16 (having its acidic substituent in the 5 position together with having the non- preferred hydrogen at the 2 position of the indole nucleus, viz., R<sub>2</sub> in formula I) is much less active.

#### Assay Example 2

##### Method:

Male Hartley strain guinea pigs (500-700g) were killed by cervical dislocation and their heart and lungs removed intact and placed in aerated (95% O<sub>2</sub>:5% CO<sub>2</sub>) Krebs buffer. Dorsal pleural strips (4x1x25mm) were dissected from intact parenchymal segments (8x4x25mm) cut parallel to the outer edge of the lower lung lobes. Two adjacent pleural strips, obtained from a single lobe and representing a single tissue sample, were tied at either end and independently attached to a metal support rod. One rod was attached to a Grass force-displacement transducer ( Model FTO3C, product of Grass Medical Instruments Co., Quincy, MA, USA). Changes in isometric tension were displayed on a monitor and thermal recorder (product of Modular Instruments, Malvern, PA). All tissues were placed in 10 ml jacketed tissue baths maintained at 37°C. The tissue baths were continuously aerated and contained a modified Krebs solution of the following composition (millimolar) NaCl, 118.2; KCl, 4.6; CaCl<sub>2</sub>·2H<sub>2</sub>O, 2.5; MgSO<sub>4</sub>·7H<sub>2</sub>O, 1.2; NaHCO<sub>3</sub>, 24.8; KH<sub>2</sub>PO<sub>4</sub>, 1.0; and dextrose, 10.0. Pleural strips from the opposite lobes of the lung were used for paired experiments. Preliminary data generated from tension/response curves demonstrated that resting tension of 800mg was optimal. The tissues were allowed to equilibrate for 45 min. as the bath fluid was changed periodically.

##### Cumulative concentration-response curves:

Initially tissues were challenged 3 times with KCl (40 mM) to test tissue viability and to obtain a consistent

response. After recording the maximal response to KCl, the tissues were washed and allowed to return to base-line before the next challenge. Cumulative concentration-response curves were obtained from pleural strips by increasing the agonist concentration (sPLA<sub>2</sub>) in the tissue bath by half-log<sub>10</sub> increments while the previous concentration remained in contact with the tissues (Ref.1, supra.) Agonist concentration was increased after reaching the plateau of the contraction elicited by the preceding concentration. One concentration-response curve was obtained from each tissue. To minimize variability between tissues obtained from different animals, contractile responses were expressed as a percentage of the maximal response obtained with the final KCl challenge. When studying the effects of various drugs on the contractile effects of sPLA<sub>2</sub>, the compounds and their respective vehicles were added to the tissues 30 min. prior to starting the sPLA<sub>2</sub> concentration-response curves.

#### Statistical analysis:

Data from different experiments were pooled and presented as a percentage of the maximal KCl responses (mean  $\pm$  S.E.). To estimate the drug induced rightward shifts in the concentration response curves, the curves were analyzed simultaneously using statistical nonlinear modeling methods similar to those described by Waud (1976), Equation 26, p. 163, (Ref.2). The model includes four parameters: the maximum tissue response which was assumed the same for each curve, the ED<sub>50</sub> for the control curve, the steepness of the curves, and the pA<sub>2</sub>, the concentration of antagonist that requires a two-fold increase in agonist to achieve an equivalent response. The Schild slope was determined to be 1, using statistical nonlinear modeling methods similar to those described by Waud (1976), Equation 27, p. 164 (Ref. 2). The Schild slope equal to 1 indicates the model is consistent with the assumptions of a competitive antagonist; therefore, the pA<sub>2</sub> may be interpreted as the apparent K<sub>B</sub>, the dissociation constant of the inhibitor.

To estimate the drug-induced suppression of the maximal responses, sPLA<sub>2</sub> responses (10 ug/ml) were determined in the absence and presence of drug, and percent suppression was calculated for each pair of tissues.

Representative examples of inhibitory activities are presented in Table 2, below.

Ref. 1 - van, J.M.: Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch. Int. Pharmacodyn. Ther., 143: 299-330, 1963.

Ref. 2 - Waud, D.: Analysis of dose-response relationships. in Advances in General and Cellular Pharmacology eds Narahashi, Bianchi 1:145-178, 1976.

Results of Human Secreted Phospholipase A<sub>2</sub> Inhibition Tests on guinea pig lung tissue


Table II

Compound of Example No.	Tissue test secreted PLA <sub>2</sub> Apparent K <sub>B</sub> nM
1	143 $\pm$ 67
3 (Na salt)	67.6 $\pm$ 11.8
9	88.7 $\pm$ 18.2
10 (Na salt)	110 $\pm$ 10
11	57 $\pm$ 11
14	75 $\pm$ 9

While the present invention has been illustrated above by certain specific embodiments, it is not intended that these specific examples should limit the scope of the invention as described in the appended claims.

#### Claims

1. A 1H-indole-3-glyoxyamide of the invention represented by the formula (I);



wherein ;

each X is independently oxygen or sulfur;

R<sub>1</sub> is selected from groups (a), (b) and (c) where;

20 (a) is C<sub>7</sub>-C<sub>20</sub> alkyl, C<sub>7</sub>-C<sub>20</sub> alkenyl, C<sub>7</sub>-C<sub>20</sub> alkynyl, carbocyclic radicals, or heterocyclic radicals, or  
(b) is a member of (a) substituted with one or more independently selected non-interfering substituents;  
or

25 (c) is the group -(L)-R<sub>80</sub>; where, -(L)- is a divalent linking group of 1 to 12 atoms selected from carbon, hydrogen, oxygen, nitrogen, and sulfur; wherein the combination of atoms in -(L)- are selected from the group consisting of (i) carbon and hydrogen only, (ii) sulfur only, (iii) oxygen only, (iv) nitrogen and hydrogen only, (v) carbon, hydrogen, and sulfur only, and (vi) and carbon, hydrogen, and oxygen only; and where R<sub>80</sub> is a group selected from (a) or (b);

R<sub>2</sub> is hydrogen, halo, C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>3</sub>-C<sub>4</sub> cycloalkyl, C<sub>3</sub>-C<sub>4</sub> cycloalkenyl, -O-(C<sub>1</sub>-C<sub>2</sub> alkyl), -S-(C<sub>1</sub>-C<sub>2</sub> alkyl), or a non-interfering substituent having a total of 1 to 3 atoms other than hydrogen;

30 R<sub>4</sub> and R<sub>5</sub> are independently selected from hydrogen, a non-interfering substituent, or the group, -(L<sub>a</sub>)-(acidic group); wherein -(L<sub>a</sub>)- is an acid linker having an acid linker length of 1 to 4; provided, that at least one of R<sub>4</sub> and R<sub>5</sub> must be the group, -(L<sub>a</sub>)-(acidic group);


35 R<sub>6</sub> and R<sub>7</sub> are each independently selected from hydrogen, non-interfering substituents, carbocyclic radicals, carbocyclic radicals substituted with non-interfering substituents, heterocyclic radicals, and heterocyclic radicals substituted with non-interfering substituents.

2. The compound of Claim 1 wherein;

(i) both X are oxygen;

(ii) R<sub>2</sub> is selected from the group; halo, cyclopropyl, methyl, ethyl, and propyl;

40 (iii) linking group -(L)- of R<sub>1</sub> is an alkylene chain of 1 or 2 carbon atoms and R<sub>80</sub> is a substituted or unsubstituted group selected from the group consisting of cycloalkyl, cycloalkenyl, phenyl, naphthyl, norbornanyl, bicycloheptadienyl, tolulyl, xylenyl, indenyl, stilbenyl, terphenyl, diphenylethylenyl, phenylcyclohexenyl, acenaphthylenyl, and anthracenyl, biphenyl, bibenzyl and related bibenzyl homologues represented by the formula (bb),




55 where n is a number from 1 to 8; and the substituents for R<sub>80</sub> are independently selected from the group consisting of halo, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>1</sub>-C<sub>10</sub> alkoxy, -S-(C<sub>1</sub>-C<sub>10</sub> alkyl), and C<sub>1</sub>-C<sub>10</sub> haloalkyl,

(iv) the (acidic group) on the group -(L<sub>a</sub>)-(acidic group) of R<sub>4</sub> or R<sub>5</sub> is selected from:


-5-tetrazolyl,

-SO<sub>3</sub>H,

5




10




15

20




25




30

35






40

45




50


55



where  $n$  is 1 to 8,  $R_{89}$  is a metal or  $C_1$ - $C_{10}$  alkyl, and  $R_{99}$  is hydrogen or  $C_1$ - $C_{10}$  alkyl;  
 (v) provided  $R_4$  is the group,  $-(L_a)$ -(acidic group), then,  $R_4$  is a substituent having an acid linker with an acid linker length of 2 or 3 and the acid linker group,  $-(L_a)$ -, for  $R_4$  is represented by the formula;




where  $Q$  is selected from the group  $-(CH_2)$ -,  $-O$ -,  $-NH$ -, and  $-S$ -, and  $R_{84}$  and  $R_{85}$  are each independently selected from hydrogen,  $C_1$ - $C_{10}$  alkyl, aryl,  $C_1$ - $C_{10}$  alkaryl,  $C_1$ - $C_{10}$  aralkyl, carboxy, carbalkoxy, and halo;  
 (vi) provided  $R_5$  is the group,  $-(L_a)$ -(acidic group), then,  $R_5$  is a substituent having an acid linker with an acid linker length of 3 to 8 atoms and the acid linker group,  $-(L_a)$ -, for  $R_5$  is selected from;



where r is a number from 1 to 7, s is 0 or 1, and Q is selected from the group  $-(CH_2)-$ ,  $-O-$ ,  $-NH-$ , and  $-S-$ , and  $R_{84}$  and  $R_{85}$  are each independently selected from hydrogen,  $C_1-C_{10}$  alkyl, aryl,  $C_1-C_{10}$  alkaryl,  $C_1-C_{10}$  aralkyl, carboxy, carbalkoxy, and halo; and,

(vii)  $R_6$  and  $R_7$  are each independently selected from hydrogen and non-interfering substituents, with the non-interfering substituents being selected from the group consisting of;  $C_1-C_6$  alkyl,  $C_1-C_6$  alkenyl,  $C_1-C_6$  alkynyl,  $C_7-C_{12}$  aralkyl,  $C_7-C_{12}$  alkaryl,  $C_3-C_8$  cycloalkyl,  $C_3-C_8$  cycloalkenyl, phenyl, tolulyl, xylenyl, biphenyl,  $C_1-C_6$  alkoxy,  $C_1-C_6$  alkenyloxy,  $C_1-C_6$  alkynyloxy,  $C_2-C_{12}$  alkoxyalkyl,  $C_2-C_{12}$  alkoxyalkyloxy,  $C_2-C_{12}$  alkylcarbonyl,  $C_2-C_{12}$  alkylcarbonylamino,  $C_2-C_{12}$  alkoxyamino,  $C_2-C_{12}$  alkoxyaminocarbonyl,  $C_2-C_{12}$  alkylamino,  $C_1-C_6$  alkylthio,  $C_2-C_{12}$  alkylthiocarbonyl,  $C_1-C_6$  alkylsulfinyl,  $C_1-C_6$  alkylsulfonyl,  $C_2-C_6$  haloalkoxy,  $C_1-C_6$  haloalkylsulfonyl,  $C_2-C_6$  haloalkyl,  $C_1-C_6$  hydroxyalkyl,  $-C(O)O(C_1-C_6$  alkyl),  $-(CH_2)_n-O-(C_1-C_6$  alkyl), benzyloxy, phenoxy, phenylthio,  $-(CONHSO_2R)$ ,  $-CHO$ , amino, amidino, bromo, carbamyl, carboxyl, carbalkoxy,  $-(CH_2)_n-CO_2H$ , chloro, cyano, cyanoguanidiny, fluoro, guanidino, hydrazide, hydrazino, hydrazido, hydroxy, hydroxyamino, iodo, nitro, phosphono,  $-SO_3H$ , thioacetal, thiocarbonyl, and  $C_1-C_6$  carbonyl; where n is from 1 to 8.

3. A 1H-indole-3-glyoxylamide of the invention represented by the formula (II) or a pharmaceutically acceptable salt, solvate, or prodrug derivatives thereof:




wherein ;

each X is independently oxygen or sulfur;

$R_{11}$  is selected from groups (a), (b) and (c) where;

(a) is  $C_7-C_{20}$  alkyl,  $C_7-C_{20}$  alkenyl,  $C_7-C_{20}$  alkynyl; or a carbocyclic radical selected from the group cycloalkyl, cycloalkenyl, phenyl, naphthyl, norbornanyl, bicycloheptadienyl, tolulyl, xylenyl, indenyl, stilbenyl, terphenyl, diphenylethylenyl, phenyl-cyclohexenyl, acenaphthylenyl, and anthracenyl, biphenyl, bibenzyl and related bibenzyl homologues represented by the formula (bb),




where n is a number from 1 to 8; or

(b) is a member of (a) substituted with one or more independently selected non-interfering substituents selected from the group consisting of  $C_1-C_6$  alkyl,  $C_1-C_6$  alkenyl,  $C_1-C_6$  alkynyl,  $C_7-C_{12}$  aralkyl,  $C_7-C_{12}$  alkaryl,  $C_3-C_8$  cycloalkyl,  $C_3-C_8$  cycloalkenyl, phenyl, tolulyl, xylenyl, biphenyl,  $C_1-C_6$  alkoxy,  $C_1-C_6$  alkenyloxy,  $C_1-C_6$  alkynyloxy,  $C_2-C_{12}$  alkoxyalkyl,  $C_2-C_{12}$  alkoxyalkyloxy,  $C_2-C_{12}$  alkylcarbonyl,  $C_2-C_{12}$  alkylcarbonylamino,  $C_2-C_{12}$  alkoxyamino,  $C_2-C_{12}$  alkoxyaminocarbonyl,  $C_1-C_{12}$  alkylamino,  $C_1-C_6$  alkylthio,  $C_2-C_{12}$  alkylthiocarbonyl,  $C_1-C_6$  alkylsulfinyl,  $C_1-C_6$  alkylsulfonyl,  $C_2-C_6$  haloalkoxy,  $C_1-C_6$  haloalkylsulfonyl,  $C_2-C_6$  haloalkyl,  $C_1-C_6$  hydroxyalkyl,  $-C(O)O(C_1-C_6$  alkyl),  $-(CH_2)_n-O-(C_1-C_6$  alkyl), benzyloxy, phenoxy, phenylthio,  $-(CONHSO_2R)$ ,  $-CHO$ , amino, amidino, bromo, carbamyl, carboxyl, carbalkoxy,

-(CH<sub>2</sub>)<sub>n</sub>-CO<sub>2</sub>H, chloro, cyano, cyanoguanidiny, fluoro, guanidino, hydrazide, hydrazino, hydrazido, hydroxy, hydroxyamino, iodo, nitro, phosphono, -SO<sub>3</sub>H, thioacetal, thiocarbonyl, and C<sub>1</sub>-C<sub>8</sub> carbonyl; where n is from 1 to 8;

(c) is the group -(L<sub>1</sub>)-R<sub>81</sub>; where, -(L<sub>1</sub>)- is a divalent linking group having the formula;



where,

R<sub>84</sub> and R<sub>85</sub> are each independently selected from hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl, carboxyl, carbalkoxy, or halo;

p is 1 to 5,


Z is a bond, -(CH<sub>2</sub>)-, -O-, -N(C<sub>1</sub>-C<sub>10</sub> alkyl)-, -NH-, or -S-; and

where R<sub>81</sub> is a group selected from (a) or (b);

R<sub>12</sub> is hydrogen, halo, C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>3</sub>-C<sub>4</sub> cycloalkyl, C<sub>3</sub>-C<sub>4</sub> cycloalkenyl, -O-(C<sub>1</sub>-C<sub>2</sub> alkyl), or -S-(C<sub>1</sub>-C<sub>2</sub> alkyl);


R<sub>14</sub> and R<sub>15</sub> are independently selected from hydrogen, a non-interfering substituent, or the group, -(L<sub>a</sub>)-(acidic group); provided that at least one of R<sub>14</sub> or R<sub>15</sub> must be the group, -(L<sub>a</sub>)-(acidic group); and further provided that,

when R<sub>14</sub> is -(L<sub>a</sub>)-(acidic group) then R<sub>14</sub> is a substituent having an acid linker with an acid linker length of 2 or 3 and the acid linker group, -(L<sub>a</sub>)-, for R<sub>14</sub> is represented by the formula;



where Q is selected from the group -(CH<sub>2</sub>)-, -O-, -NH-, and -S-, and R<sub>84</sub> and R<sub>85</sub> are each independently selected from hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl, aryl, C<sub>1</sub>-C<sub>10</sub> alkaryl, C<sub>1</sub>-C<sub>10</sub> aralkyl, hydroxy, and halo; and further provided that,

when R<sub>15</sub> is -(L<sub>a</sub>)-(acidic group) then R<sub>15</sub> is a substituent having an acid linker with an acid linker length of 3 to 8 atoms and the acid linker group, -(L<sub>a</sub>)-, for R<sub>15</sub> is selected from;




where r is a number from 1 to 7, s is 0 or 1, and Q is selected from the group -(CH<sub>2</sub>)-, -O-, -NH-, and -S-, and R<sub>84</sub> and R<sub>85</sub> are each independently selected from hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl, aryl, C<sub>1</sub>-C<sub>10</sub> alkaryl, C<sub>1</sub>-C<sub>10</sub> aral-

kyl, carboxy, carbalkoxy, and halo;


$R_{16}$  and  $R_{17}$  are each independently selected from hydrogen, non-interfering substituents, selected from the group consisting of  $C_1$ - $C_8$  alkyl,  $C_1$ - $C_8$  alkenyl,  $C_1$ - $C_8$  alkynyl,  $C_7$ - $C_{12}$  aralkyl,  $C_7$ - $C_{12}$  alkaryl,  $C_3$ - $C_8$  cycloalkyl,  $C_3$ - $C_8$  cycloalkenyl, phenyl, tolyl, xyl, biphenyl,  $C_1$ - $C_8$  alkoxy,  $C_1$ - $C_8$  alkenyloxy,  $C_1$ - $C_8$  alkynyloxy,  $C_2$ - $C_{12}$  alkoxyalkyl,  $C_2$ - $C_{12}$  alkoxyalkyloxy,  $C_2$ - $C_{12}$  alkylcarbonyl,  $C_2$ - $C_{12}$  alkylcarbonylamino,  $C_2$ - $C_{12}$  alkoxyamino,  $C_2$ - $C_{12}$  alkoxyaminocarbonyl,  $C_2$ - $C_{12}$  alkylamino,  $C_1$ - $C_8$  alkylthio,  $C_2$ - $C_{12}$  alkylthiocarbonyl,  $C_1$ - $C_8$  alkylsulfinyl,  $C_1$ - $C_8$  alkylsulfonyl,  $C_2$ - $C_8$  haloalkoxy,  $C_1$ - $C_8$  haloalkylsulfonyl,  $C_2$ - $C_8$  haloalkyl,  $C_1$ - $C_8$  hydroxyalkyl,  $-C(O)O(C_1-C_8 \text{ alkyl})$ ,  $-(CH_2)_n-O-(C_1-C_8 \text{ alkyl})$ , benzyloxy, phenoxy, phenylthio,  $-(CONH-SO_2R)$ ,  $-CHO$ , amino, amidino, bromo, carbamyl, carboxyl, carbalkoxy,  $(CH_2)_n-CO_2H$ , chloro, cyano, cyanoguanidiny, fluoro, guanidino, hydrazide, hydrazino, hydrazido, hydroxy, hydroxyamino, iodo, nitro, phosphono,  $-SO_3H$ , thioacetal, thiocarbonyl, and  $C_1$ - $C_8$  carbonyl; where  $n$  is from 1 to 8.

4. A 1H-indole-3-glyoxylamide of the invention represented by the formula (III) or a pharmaceutically acceptable salt, solvate, or prodrug derivatives thereof:



wherein;

$R_{21}$  is the group  $-(L_2)-R_{81}$ ; where,  $-(L_2)-$  is a divalent linking group having the formula;




$p$  is 1 to 5,

and  $R_{81}$  is a group selected from (a) or (b);


where;

(a) is selected from the group consisting of



and











where  $R_{10}$  is a radical independently selected from halo,  $C_1$ - $C_{10}$  alkyl,  $C_1$ - $C_{10}$  alkoxy,  $-S-(C_1-C_{10})$  alkyl, and  $C_1$ - $C_{10}$  haloalkyl and  $t$  is a number from 0 to 5; and

(b) is a member of (a) substituted with one or more independently selected non-interfering substituents selected from the group consisting of  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_2$ - $C_6$  haloalkoxy,  $C_2$ - $C_6$  haloalkyl, bromo, chloro, fluoro, or iodo;

$R_{24}$  is selected from hydrogen,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_2$ - $C_6$  haloalkoxy,  $C_2$ - $C_6$  haloalkyl, bromo, chloro, fluoro, or iodo, or the group,  $-(L_a)$ -(acidic group), wherein the acid linker  $-(L_a)-$  for  $R_{24}$  is selected from the group consisting of;



and






where R is alkyl, and the acidic group is selected from





-CO<sub>2</sub>H

-SO<sub>3</sub>H


-P(O)(OH)<sub>2</sub>

R<sub>25</sub> is selected from hydrogen, C<sub>1</sub>-C<sub>8</sub> alkyl, C<sub>1</sub>-C<sub>8</sub> alkoxy, C<sub>2</sub>-C<sub>8</sub> haloalkoxy, C<sub>2</sub>-C<sub>8</sub> haloalkyl, bromo, chloro, fluoro, or iodo, or the group, -(L<sub>a</sub>)-(acidic group), wherein the acid linker -(L<sub>a</sub>)- for R<sub>25</sub> is selected from group consisting of;






and




wherein  $\text{R}_{84}$  and  $\text{R}_{85}$  are each independently selected from hydrogen,  $\text{C}_1$ - $\text{C}_{10}$  alkyl, aryl,  $\text{C}_1$ - $\text{C}_{10}$  alkaryl,  $\text{C}_1$ - $\text{C}_{10}$  aralkyl, carboxy, carbalkoxy, and halo, and the acidic group is selected from

$-\text{CO}_2\text{H}$  ,  
 $-\text{SO}_3\text{H}$  ,




provided that at least one of  $R_{24}$  or  $R_{25}$  must be the group,  $-(L_a)-(acidic\ group)$ ; and  $R_{26}$ , and  $R_{27}$  are each independently selected from hydrogen, or  $C_1-C_6$  alkyl,  $C_1-C_6$  alkoxy,  $C_2-C_6$  haloalkoxy,  $C_2-C_6$  haloalkyl, bromo, chloro, fluoro, or iodo.

5. The compound of claim 4 where for formula III only one of  $R_{24}$  or  $R_{25}$  are  $-(L_a)-(acidic\ group)$ ,  $R_{26}$  and  $R_{27}$  are hydrogen, and the acidic group is carboxyl.
6. A 1H-indole-3-glyoxylamide or a pharmaceutically acceptable salt, solvate, or prodrug derivatives thereof selected from the group consisting of compounds (A) thru (P) :
  - (A) [[3-(2-Amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid,
  - (B) dl-2-[[3-(2-Amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]propanoic acid,
  - (C) [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid,
  - (D) [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-3-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid,
  - (E) [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-4-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]acetic acid,
  - (F) [[3-(2-Amino-1,2-dioxoethyl)-1-[(2,6-dichlorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid
  - (G) [[3-(2-Amino-1,2-dioxoethyl)-1-[4-(fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]acetic acid,
  - (H) [[3-(2-Amino-1,2-dioxoethyl)-2-methyl-1-([1-naphthalenyl)methyl]-1H-indol-4-yl]oxy]acetic acid,
  - (I) [[3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid,
  - (J) [[3-(2-Amino-1,2-dioxoethyl)-1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]acetic acid,
  - (K) [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-ethyl-1H-indol-4-yl]oxy]acetic acid,
  - (L) [[3-(2-amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-propyl-1H-indol-4-yl]oxy]acetic acid,
  - (M) [[3-(2-Amino-1,2-dioxoethyl)-2-cyclopropyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid,
  - (N) [[3-(2-Amino-1,2-dioxoethyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-cyclopropyl-1H-indol-4-yl]oxy]acetic acid,
  - (O) 4-[[3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-5-yl]oxy]butanoic acid, and
  - (P) mixtures of (A) thru (O).
7. A 1H-indole-3-glyoxylamide selected from the formulae:



or



or prodrug derivatives thereof.

8. A pharmaceutical formulation comprising as active ingredient a 1H-indole-3-glyoxylamide as claimed in claims 1 to 7 together with one or more pharmaceutically acceptable carriers or diluents therefor.
9. A 1H-indole-3-glyoxylamide compound as claimed in claims 1 to 7, for use as a pharmaceutical for inhibiting sPLA<sub>2</sub> mediated release of fatty acid.
10. A 1H-indole-3-glyoxylamide compound as claimed in claims 1 to 7, for use as a pharmaceutical for treating a mammal, including a human, to alleviate the pathological effects of septic shock, adult respiratory distress syndrome, pancreatitis, trauma, bronchial asthma, allergic rhinitis, and rheumatoid arthritis.



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 95 30 2166

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
A	WO-A-91 06537 (AMERICAN HOME PRODUCTS CORPORATION) * claims *	1,9	C07D209/22 A61K31/40
P,X	EP-A-0 620 215 (ELI LILLY AND COMPANY) * page 21-34 *	1,9	
P,A	EP-A-0 620 214 (ELI LILLY AND COMPANY) * claims *	1,9	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			C07D A61K
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 15 June 1995	Examiner Van Bijlen, H
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone  Y : particularly relevant if combined with another document of the same category  A : technological background  O : non-written disclosure  P : intermediate document</p> <p>T : theory or principle underlying the invention  E : earlier patent document, but published on, or after the filing date  D : document cited in the application  L : document cited for other reasons  A : member of the same patent family, corresponding document</p>			

EPO FORM 1503 (3.12.92) (P04C01)

# DEUTSCHES PATENTAMT

München, den 9. April 1997

☎ (089) 2195 - 3204

Aktenzeichen: 196 36 150.8

Anmelder:  
Asta Medica AG

Deutsches Patentamt - 80297 München

Arzneimittelwerk Dresden GmbH  
Fachbereich Patente  
Meißner Str.35

01445 Radebeul

Ihr Zeichen: 96/09 PH/Nau

Bitte Aktenzeichen und Anmelder bei  
allen Eingaben und Zahlungen angeben  
Zutreffendes ist angekreuzt ☒ und/oder aus ausgefüllt

## Ergebnis einer Druckschriftenermittlung

Auf den Antrag des  
wirksam am 6. September 1996 gemäß x § 43 Patentgesetz ☐ § 7 Gebrauchsmustergesetz  
sind die auf den beigefügten Anlagen angegebenen öffentlichen Druckschriften ermittelt worden.  
Ermittelt wurde in folgenden Patentklassen:

Klasse/Gruppe	Prüfer	Patentabt.
C07D 401/12, 401/14	Dr. Stadler	44
C07D 209/04	Dr. Parvisi	44
A61K 31/44, 31/495	Dr. Knittl	41

Die Recherche im Deutschen Patentamt stützt sich auf die Patentliteratur folgender Länder und Organisationen:

Deutschland (DE, DD), Österreich, Schweiz, Frankreich, Großbritannien, USA, Japan (Abstracts),  
UDSSR (Abstracts), Europäisches Patentamt, WIPO.

Recherchiert wurde außerdem in folgenden Datenbanken:

### Anlagen:

Anlagen 1, 2 und 3 zur Mitteilung der ermittelten Druckschriften

15 Druckschrift(en) bzw. Ablichtung(en)

**Patentabteilung 11**  
**Recherchen-Leitstelle**



196 36 150.8

## Anlage 1

zur Mitteilung über die ermittelten Druckschriften  
gemäß § 43 des Patentgesetzes

## Druckschriften:

US 31 35 794

EP 06 75 110 A1

## Literatur:

GLAMKOWSKI, Edward J., REITANO, Philip A.:  
Synthesis of 3-(4-Acylaminopiperazin-1-ylalkyl)  
indoles as Potential Antihypertensive Agents.  
In: Journal of Medicinal Chemistry, 1997, Vol.20,  
No.11, S.1485-1489;  
ARCHIBALD, John L., FREED, Meier E.: 1,4-Bis  
(2-indol-3-ylethyl)piperazines. In: Journal  
Of Medicinal Chemistry, 1974, Vol.17, No.7,  
S.745-747;  
DOMSCHKE, Günter, FÜRST, Hans: Notiz zur  
Darstellung einiger [1-Benzyl-2-methyl-5-  
methoxyindolyl-(3)]-glyoxylsäureamide. In:  
Chem. Ber. 94, 1961, S.2353-2355;  
LIPP, Maria, u.a.: Notiz über einige Derivate  
der [5-Benzyl-2-methyl-5-methoxyindolyl-(3)]-glyoxylsäure. In:  
Chem. Ber. 91, 1958, S.242,243;  
Chemical Abstracts:  
Vol.65, 1966, Ref. 3871c;  
Vol.60, 1964, Ref. 9293g;  
Vol.67, 1967, Ref. 53968m;



## Zahlungshinweise

1. Die **Gebühren** können außer durch Barzahlung entrichtet werden:
  - a) durch Übergabe oder Übersendung
    - von Gebührenmarken des Deutschen Patentamts,
    - von Schecks, die auf ein Kreditinstitut in der Bundesrepublik Deutschland gezogen sind,
    - eines Auftrags zur Abbuchung von dem hierfür zugelassenen Abbuchungskonto gemäß Bekanntmachung und Mitteilung Nr. 1 und 2/90 jeweils vom 15. Dezember 1989 (Bl.f.PMZ 1990, S. 1 und 2) sowie Nr. 6/92 vom 27. Februar 1992 (Bl.f.PMZ 1992, S. 177 und 178).
  - b) durch Überweisung auf eines der umseitig angegebenen Konten der Zahlstelle
  - c) durch Bareinzahlung (mit Zahlschein bei der Postbank oder bei allen anderen Banken oder Sparkassen) auf eines der umseitig angegebenen Konten der Zahlstelle.
2. Bei jeder Zahlung sind das vollständige **Aktenzeichen**, die genaue Bezeichnung des **Anmelders (Inhabers)** und die Bezeichnung der **Gebühr** (z.B. Anmeldegebühr, .....Jahresgebühr) in deutlicher Schrift anzugeben.
3. **Als Einzahlungstag** gilt gemäß § 3 der Verordnung über die Zahlung der Gebühren des Deutschen Patentamts und des Bundespatentgerichts vom 15. Oktober 1991 (BGBl. I S. 2012)
  - a) bei Übergabe oder Übersendung von Gebührenmarken der Tag des Eingangs;
  - b) bei Übergabe oder Übersendung von Schecks oder Abbuchungsaufträgen der Tag des Eingangs beim Deutschen Patentamt oder Bundesgericht, sofern die Einlösung bei Vorlage erfolgt (da Abbuchungsaufträge auch per Telekopie wirksam übermittelt werden können, ist es mit dieser Zahlungsart möglich, entsprechende Zahlungen noch bis 24.00 Uhr des letzten Tages der Frist vorzunehmen);
  - c) bei Bareinzahlung mit Zahlschein bei der Postbank und allen anderen Banken und Sparkassen auf ein Konto des Deutschen Patentamts der Tag der Einzahlung (in diesem Falle ist vom Einzahler jedoch darauf zu achten, daß ihm der Tag (Datum) der Einzahlung von dem Geldinstitut auf dem Einzahlungsbeleg, Durchschlag etc. hinreichend deutlich bestätigt wird);
  - d) im übrigen der Tag, an dem der Betrag bei der Zahlstelle des Deutschen Patentamts in München oder Berlin eingeht oder auf dem Konto einer dieser Stellen gutgeschrieben wird.

## Gebrauchsmusterabzweigung

Der Anmelder einer nach dem 1. Januar 1987 mit Wirkung für die Bundesrepublik Deutschland eingereichten Patentanmeldung kann eine Gebrauchsmusteranmeldung, die den gleichen Gegenstand betrifft, einreichen und gleichzeitig den Anmeldetag der früheren Patentanmeldung in Anspruch nehmen. Diese Abzweigung (§ 5 Gebrauchsmustergesetz) ist bis zum Ablauf von 2 Monaten nach dem Ende des Monats möglich, in dem die Patentanmeldung durch rechtskräftige Zurückweisung, freiwillige Rücknahme oder Rücknahmefiktion erledigt, ein Einspruchsverfahren abgeschlossen oder - im Falle der Erteilung des Patents - die Frist für die Beschwerde gegen den Erteilungsbeschluß fruchtlos verstrichen ist. Ausführliche Informationen über die Erfordernisse einer Gebrauchsmusteranmeldung, einschließlich der Abzweigung, enthält das Merkblatt für Gebrauchsmusteranmelder (G 6181), welches kostenlos beim Patentamt und den Patentauslegestellen erhältlich ist.

# DEUTSCHES PATENTAMT

Deutsches Patentamt · 80297 München

DATUM: 21.03.97 SEITE: 1

196 36 150.8

## Anlage 2

zur Mitteilung über die ermittelten Druckschriften  
gemäß § 43 des Patentgesetzes

### Sonstiges:

\$Vol. 79, 1973, Ref. 87491p;  
Vol. 86, 1977, Ref. 106379w;  
Vol. 120, 1994, Ref. 125105r;  
Vol. 92, 1980, Ref. 128647h;  
Vol. 70, 1969, Ref. 37598x;  
Vol. 70, 1969, Ref. 115007v;

## Zahlungshinweise

1. Die **Gebühren** können außer durch Barzahlung entrichtet werden:
  - a) durch Übergabe oder Übersendung
    - von Gebührenmarken des Deutschen Patentamts,
    - von Schecks, die auf ein Kreditinstitut in der Bundesrepublik Deutschland gezogen sind,
    - eines Auftrags zur Abbuchung von dem hierfür zugelassenen Abbuchungskonto gemäß Bekanntmachung und Mitteilung Nr. 1 und 2/90 jeweils vom 15. Dezember 1989 (Bl.f.PMZ 1990, S. 1 und 2) sowie Nr. 6/92 vom 27. Februar 1992 (Bl.f.PMZ 1992, S. 177 und 178).
  - b) durch Überweisung auf eines der umseitig angegebenen Konten der Zahlstelle
  - c) durch Bareinzahlung (mit Zahlschein bei der Postbank oder bei allen anderen Banken oder Sparkassen) auf eines der umseitig angegebenen Konten der Zahlstelle.
2. Bei jeder Zahlung sind das vollständige **Aktenzeichen**, die genaue Bezeichnung des **Anmelders (Inhabers)** und die Bezeichnung der **Gebühr** (z.B. Anmeldegebühr, .....Jahresgebühr) in deutlicher Schrift anzugeben.
3. **Als Einzahlungstag** gilt gemäß § 3 der Verordnung über die Zahlung der Gebühren des Deutschen Patentamts und des Bundespatentgerichts vom 15. Oktober 1991 (BGBl. I S. 2012)
  - a) bei Übergabe oder Übersendung von Gebührenmarken der Tag des Eingangs;
  - b) bei Übergabe oder Übersendung von Schecks oder Abbuchungsaufträgen der Tag des Eingangs beim Deutschen Patentamt oder Bundesgericht, sofern die Einlösung bei Vorlage erfolgt (da Abbuchungsaufträge auch per Telekopie wirksam übermittelt werden können, ist es mit dieser Zahlungsart möglich, entsprechende Zahlungen noch bis 24.00 Uhr des letzten Tages der Frist vorzunehmen);
  - c) bei Bareinzahlung mit Zahlschein bei der Postbank und allen anderen Banken und Sparkassen auf ein Konto des Deutschen Patentamts der Tag der Einzahlung (in diesem Falle ist vom Einzahler jedoch darauf zu achten, daß ihm der Tag (Datum) der Einzahlung von dem Geldinstitut auf dem Einzahlungsbeleg, Durchschlag etc. hinreichend deutlich bestätigt wird);
  - d) im übrigen der Tag, an dem der Betrag bei der Zahlstelle des Deutschen Patentamts in München oder Berlin eingeht oder auf dem Konto einer dieser Stellen gutgeschrieben wird.

## Gebrauchsmusterabzweigung

Der Anmelder einer nach dem 1. Januar 1987 mit Wirkung für die Bundesrepublik Deutschland eingereichten Patentanmeldung kann eine Gebrauchsmusteranmeldung, die den gleichen Gegenstand betrifft, einreichen und gleichzeitig den Anmeldetag der früheren Patentanmeldung in Anspruch nehmen. Diese Abzweigung (§ 5 Gebrauchsmustergesetz) ist bis zum Ablauf von 2 Monaten nach dem Ende des Monats möglich, in dem die Patentanmeldung durch rechtskräftige Zurückweisung, freiwillige Rücknahme oder Rücknahmefiktion erledigt, ein Einspruchsverfahren abgeschlossen oder - im Falle der Erteilung des Patents - die Frist für die Beschwerde gegen den Erteilungsbeschuß - fruchtlos verstrichen ist. Ausführliche Informationen über die Erfordernisse einer Gebrauchsmusteranmeldung, einschließlich der Abzweigung, enthält das Merkblatt für Gebrauchsmusteranmelder (G 6181), welches kostenlos beim Patentamt und den Patentauslegestellen erhältlich ist.

## DEUTSCHES PATENTAMT

**80297 München**

## Anlage 2

**zur Mitteilung der ermittelten Druckschriften**

### Aktenzeichen

196 36 150.8

Erläuterungen zu den ermittelten Druckschriften:		
1	2	3
Kategorie	Ermittelte Druckschriften/Erläuterungen	Betrifft Anspruch
A	US 31 35 794	
X	EP 06 75 110 A1	
A	siehe Literatur auf Anlage 1;	

**Hinweise zur Mitteilung (Vordruck P 2251)**

Eine Gewähr für die Vollständigkeit der Ermittlung wird nicht geleistet (§ 43 Abs. 7 Patentgesetz bzw. § 7 Abs. 2 Gebrauchsmustergesetz i.V.m. § 43 Abs. 7 Satz 1 Patentgesetz).

Die angegebene Patendliteratur kann in den Auslegehallen des Deutschen Patentamts, 80331 München, Zweibrückenstraße 12 oder 10969 Berlin, Gitschiner Str. 97 eingesehen werden; deutsche Patentschriften, Auslegeschriften und Offenlegungsschriften auch in den Patentinformationszentren. Ein Verzeichnis über diese Patentinformationszentren kann auf Wunsch vom Deutschen Patentamt sowie von einigen Privatfirmen bezogen werden.

**Erklärungen zur Anlage 2 (Vordruck P 2253)****Spalte 1: Kategorie**

Es bedeutet:

- X:** Druckschriften, die Neuheit oder Erfindungshöhe allein in Frage stellen
- Y:** Druckschriften, die die Erfindungshöhe zusammen mit anderen Druckschriften in Frage stellen
- A:** Allgemein zum Stand der Technik, technologischer Hintergrund
- O:** Nicht-schriftliche Offenbarung, z.B. ein in einer nachveröffentlichten Druckschrift abgedruckter Vortrag, der vor dem Anmelde- oder Prioritätstag öffentlich gehalten wurde
- P:** Im Prioritätsintervall veröffentlichte Druckschriften
- T:** Nachveröffentlichte, nicht kollidierende Druckschriften, die die Theorie der angemeldeten Erfindung betreffen und für ein besseres Verständnis der angemeldeten Erfindung nützlich sein können bzw. zeigen, daß der angemeldeten Erfindung zugrunde liegende Gedankengänge oder Sachverhalte falsch sein könnten
- E:** Ältere Anmeldungen gemäß § 3 Abs. 2 PatG (bei Recherchen nach § 43 PatG); ältere Patentanmeldungen oder ältere Gebrauchsmuster gemäß § 15 GbmG (bei Recherchen nach § 7 GbmG)
- D:** Druckschriften, die bereits in der Patentanmeldung genannt sind
- L:** Aus besonderen Gründen genannte Druckschriften, z.B. zum Veröffentlichungstag einer Entgeghaltung oder bei Zweifeln an der Priorität.

Im Recherchenverfahren nach § 7 GbmG werden nur die Kategorien "A" und "E" angegeben.

**Spalte 2: Ermittelte Druckschriften / Erläuterungen**

**Veröff.:** Veröffentlichungstag einer Druckschrift im Prioritätsintervall

**nr:** Nicht recherchiert, da allgemein bekannter Stand der Technik, oder nicht recherchierbar

**=:** Druckschriften, die auf dieselbe Ursprungsanmeldung zurückgehen ("Patentfamilien") oder auf die sich Referate oder Abstracts beziehen.

**"-":** Nichts ermittelt

**Spalte 3: Betroffene Ansprüche**

Hier sind die Ansprüche unter Zuordnung zu den in Spalte 2 genannten relevanten Stellen angegeben.